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Abstract
Troponin is known as a type of reliable biomarker for the detection of cardiac disorders.
Cardiac troponin I (cTnI), as a subunit of troponin, is highly sensitive to cardiac injury;
therefore, the cTnI level is used as an index to diagnose myocardial damage, particularly
acute myocardial infarction. It can be also used in cardiospecific diagnosis, risk stratification
therapeutic treatment and post risk management.

In this research, an amperometric

immunosensor was developed based on planar electrode and sandwich ELISA format. The
electrical response corresponding to biological information was obtained via four main
procedures, including electrode modification, immunoreaction, signal amplifications and
amperometric detection. Enzyme labels such as horseradish peroxide (HRP) and alkaline
phosphatase (ALP) were used for signals amplification. Since alkaline phosphatase works
better in low background current levels and has great reproducibility, it was used for
nanomaterials, chitosan, gold nanoparticle, carbon nanotube as electrode modification
investigation. The anti-cTnI antibody is detectable by electrochemical technology. Necessary
conditions and interferences of the experiment were examined. Detection range was from
0.001 ng ml-1 to 300 ng ml-1 on PDDA-MWCNT sensor, and from 0.02 ng ml-1 to 200 ng
ml-1 on chitosan-AuNPs sensor. The detection range was investigated using cyclic
voltammetry. The signal behavior recorded was linear to cTnI concentration. This behavior
makes the developed biosensor be able to widely use in clinical practice. Likewise, two
liquid substrates were catalyzed by hydroquinone and 3, 3’, 5, 5’-teteramethylbenzidine
respectively. Hydrogen peroxide (H2O2) is a product of glucose oxidizes catalyzing the
oxidation of β-D-glucose by oxygen. It is also used as an oxidizing agent in catalyzing HRP.
Hence, an HRP-based immunosensor is important in integrating an immunosensor and an
enzyme sensor for the purpose of achieving multianalyte detection compacted on one chip.
The cTnI immunosensor developed here is rapid, easy-to-use, cost-efficient and robust.

Keywords
Cardiac biomarkers, cardiac troponin I (cTnI), point-of-care, electrochemical immunosensor,
amperometric, sandwich ELISA, Horseradish peroxide, alkaline phosphatase.
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Chapter 1
1

Introduction

This chapter will introduce the background knowledge about cardiovascular disease,
various cardiac biomarkers and their clinical applications. Motivation, objective, and
outline of the thesis have also been addressed.

1.1

Cardiovascular disease

Regardless of enormous efforts and significant achievements in the precaution and
treatment of cardiovascular disease (CVD), a severe medical condition, it still accounts
for the majority of adult mortality in the present western world (McDonnell et al., 2009).
The data and statistics from America’s 2009 Centers for Disease Control and Prevention
(CDC) showed that 599,413 Americans died from heart disease (195.2 deaths in every
100,000 people), over 30 million times visit to clinic, hospital or emergency department
due to heart disease including primary diagnosis of ischemia heat disease, and up to
42.6% (635,000) cardiac condition patients residing in the nursing homes (CDC Home,
2009). In the European Union, the expense on cardiac condition is roughly 192 billion
Euro annually (Allender S, 2008). Each year, countless patients pour in the emergency
departments for medical care owning to chest pain syndrome or other forms of acute
coronary syndrome (ACS), among which less than 10% are finally diagnosed as acute
myocardial infarction (AMI) (Collinson PO, 1999; Lewandrowski et al., 2002). Through
the ages, CVD conditions have crippled our human society in terms of health care
services, medication and lost productivity.
The challenge is that symptoms, including chest pain, pressure, tightness, dyspnoea and
heartburn sensations, are not adequate for correct diagnosis in primary medical clinic.
Generally, panic disorder, stable angina, gastrointestinal disease, musculoskeletal pain
and viral infection all can cause chest pain syndromes; however the critical suspects
would be more severe cardiac conditions: heart failure (HF), thromboembolic events (TE)
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and acute coronary syndromes (ACS), especially myocardial infarction (MI) (Brieger et
al., 2004; Godfrey et al., 2006; Punukollu et al., 2005; Tomonaga et al., 2011). Figure 1.1
indicates the pathophysiology progression of acute coronary syndromes (ACS).
When the fatty streaks accumulated to a certain extent to form plaques, the rupture of
plaques and the thrombus will result in gradual deterioration, from unstable angina to
heart failure (Azzazy and Christenson, 2002). Myocardial infarction (MI) can be defined
as the non-reversible damage of cardiac myocytes caused by sustaining ischemia,
resulting in necrosis of myocardial cells. Therefore, MI is recognized as the most life
threatening cardiac condition requiring comprehensive, correct and quick diagnosis
(Mohammed and Desmulliez, 2011).

Figure 1.1: Cardiac injury: the pathophysiology of acute coronary syndromes
(ACS). Adapted from Ref. (Azzazy and Christenson, 2002).
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In 2002, the European Society of Cardiology (ESC) and the American College of
Cardiology (ACC) reached consensus and redefined the diagnosis criteria of myocardial
infarction: to conform or exclude AMI, it should meet no less than 2 conditions out of
chest pain (typical and most common symptoms), elevation of cardiac biomarkers, or
abnormal electrocardiogram (ECG) (Alpert et al., 2001; Lewandrowski et al., 2002).
Figure 2.2 classifies the ASC patients on their ECG reading. The ECG is vital for
treatment decision because patients with ST elevation usually have fibrin rich thrombus.
On the other hand, most patients with non-ST elevation myocardial infarction have clots
with abundant platelet (Azzazy and Christenson, 2002; Mizuno et al., 1992). Up to 5070% hospital admissions with chest pain syndromes present normal or ambiguous ECG
reading (Brogan and Bock, 1998; Morrow et al., 2007); thus, correct appraisal of elevated
cardiac biomarkers is a reliable approach to a proper treatment for patients. Furthermore,
the elevation of cardiac markers can indicate the type of ACS, the basic timeline since the
initial onset, and even the location of damaged cells (Mohammed and Desmulliez, 2011).

Figure 1.2: ACS clinical classification regarding electrocardiogram. Adapted from
Ref. (Azzazy and Christenson, 2002).
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1.1.1 Cardiac biomarker detection: immunoassay
Immunoassay is the interaction between antibody and antigen. Antibodies (Abs) are
proteins generated by immune system of animals and human bodies in order to response
to antigens (Ags), allochthonous substances. Every Ab has a unique structure to bind
with the corresponding Ag in a "lock and key mechanism"; therefore, the binding
between Ab and Ag is highly specific. To better utilize the benefits of antibody and
antigen interaction, especially the sensitivity and specificity, immunoassays possess
various formats. It provides the quantification and monitoring of the protein or
biomolecules, for example nucleic acids, protein molecules, drugs and metabolites, and
the pathogens (Lin et al., 2010b). Nowadays, immunoassay is a prevalent detection
method used in food safety, environmental monitoring, biotechnological investigation,
and clinical analysis. For cardiac biomarker determination and other biomarkers
detection, immunoassay is believed to be the gold-standard technique (Lin et al., 2010b;
Mohammed and Desmulliez, 2011).

More details of immunoassay will be further

discussed in Chapter 3.

1.2

Cardiac biomarkers and application

The history of cardiac biomarkers can be traced back to 1954; Ladue JS et al. reported the
unusual elevation of glutamate oxaloacetic in serum after a few hours of acute
myocardial infarction (AMI), the duration lasting for 4 to 6 days with a peak in 2 to 3 day
(Ladue JS et al., 1954). An ideal biomarker would possess the following properties
(Azzazy and Mansour, 2009; Braunwald, 2008):


Small size: quick releasing from injured tissues



Tissue specificity: exclusive in cardiac muscle



High sensitivity: abundant in cardiac tissue



Release: the concentration in plasma proportion to infarct sizing



Stability: reach peak immediately after the injury and maintain for hours



Clearance: cleared rapidly for recurrent injury diagnostic



Application: Suitable for different stage of cardiac injury and cost effective

5

Even though, the parameters mentioned above are critical for monitoring ACS potential
patients, there is no cardiac biomarker can meet all the requirements. Therefore, the
knowledge regarding characteristics of biomarkers is vital for both research and clinical
applications. Details about several cardiac biomarkers are discussed below.

1.2.1 Biomarkers of cardiac injury
1.2.1.1

Myoglobin

Myoglobin (MYO) (17.8kDa) is a small and single-chain hemeprotein of 153 amino
acids, presenting high concentration in cardiac and red muscle tissue and playing a role as
a storage site for transporting oxygen to various tissues or organs (Panteghini et al., 2004).
Due to the small molecular size and weight, myoglobin will quickly release into the
blood stream through cytoderm (cell wall), an hour or so after the onset of AMI, and then
is elevated to the peak value in 4 to 12 hours, followed by a subsequent drop to baseline
in 12 more hours (Adams et al., 1993; Gibler et al., 1990; Mair et al., 1992). Since
Myoglobin distributed in almost all the tissues, the baseline value is measured over
30 ng/ml in peripheral circulation, normally. Either cardiac or skeletal damage will cause
serum myoglobin elevated; therefore, myoglobin are used by hospitals as a negative
predictive value (rule out the diagnosis of AMI) instead of conforming the diagnosis of
AMI condition. (Lewandrowski et al., 2002; Sluss, 2006)

1.2.1.2

Creatine Kinases

Another well-known cardiac biomarker is Creatine Kinases. The measurements of CK
(molecular weight 87kDa) and CK-MB (86kDa) for diagnosing AMI have a long history.
Furthermore, the elevation of CK-MB was regarded as the traditional “gold standard” in
1980s for over two decades. CK has three subunits (three different types based on
locating organs) including MM, MB, and BB, which present in both myocardium and
skeletal tissues (Christenson and Azzazy, 1998; Lewandrowski et al., 2002).

The

concentration of CK-MM is dominant in skeletal muscle, 98% over total muscle CK. CKMB presents only 2% to 5% in healthy skeletal muscle and higher level in patients with
chronic myopathic injury and renal failure. Even though, CK-MB occupies over 20% in
the myocardium over the total myocardial CK, still less than the concentration of CK-
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MM in myocardial muscle. Therefore, the CK total elevation can be clinically applied in
diagnosing skeletal muscle injury or disorders but not cardiac specific conditions
(Lewandrowski et al., 2002). After cardiac injury, CK-MB starts to release into the
bloodstream from the injured tissue in 4 to 9 hours of the occurrence of chest pain,
reaches the peak at 24 hours and returns to normal value in 48 to 72 hours (Males et al.,
2001). Therefore, CK-MB would not be a good candidate for AMI early stage, but be
suitable for reinfarction diagnosis and critical aid tool in multimarker panel (Panteghini,
1998).
Since both myocardial and skeletal injury will cause total CK and CK-MB elevated, the
ratio of CK-MB to total CK can be calculated for distinguishing cardiac specific
conditions. Mostly, in the lab-based testing, when CK-MB is more than 5% of the total, it
can be called as suggestive AMI (Lewandrowski et al., 2002). Furthermore, regardless of
the emergence of troponin I, CK-MB remains high value in clinical application, such as
decision making in ED department (Young et al., 1991),

guidance of disposition

decisions (Hedges et al., 1996), prognosis in patients with AMI symptoms and nondiagnostic ECGs (Hoekstra et al., 1994), and a valuable indicator in multiplex assays
(Galla et al., 2006).

1.2.1.3

Cardiac Troponins

Cardiac troponins (low molecular weight 20- 25kDa) have significant sensitivity and
specificity for myocardial muscle damage; therefore, they have been regarded as the
“gold standard” for acute myocardial infarction diagnosis (Alpert et al., 2000; Martins et
al., 1996). Even though, cardiac troponins only have been measurable for three decades,
cTnT in 1989 (Katus et al., 1989) and cTnI in 1991(Bodor et al., 1992), the influence
boosted tremendous advancement of the cardiac marker measurements. Troponin, as a
regulatory complex, has three subunits on the thin filament combined with myocardial
contractile muscle to control the calcium ions bindings: troponin C (the component for
calcium binding), TnT (the tropomyosin-binding) and cTnI (the inhibitory component).
The majority of troponins were stored in the sarcomeres; both TnI and TnT present in
compartment distribution in the myocytes along with small trace in cytosolic pool (4%6%). Therefore, both troponins have the analogous releasing kinetics after myocardial

7

damage: serum TnI and TnT elevated within 4 to 9 hours, reached the peak in 12 to 24
hours and remaining high level for up to 2 weeks. Besides the specificity and wide
diagnostic window, the amino acid sequences of both TnI and TnT are suitable for
monoclonal antibody-based immunoassay overcoming the cross-reactivity of similar
proteins. Moreover, serum TnI and TnT are rarely presenting in peripheral circulation in
healthy peoples; traditionally, both troponins are less than 0.1 and 0.4 ng/ml, respectively.
Thus, tremendously rising troponin level will highly possibly indicate myocardial
necrosis (Bertinchant et al., 1996; Lewandrowski et al., 2002; Sluss, 2006; Wu et al.,
1999).
It takes several hours, similar to CK-MB, from the onset of AMI to serum troponins can
be detectable, so TnI and TnT are not ideal candidates for early AMI assessment. While,
among all the cardiac biomarkers, the superiority of cardiac TnI and TnT has been
foreground by the highest cardiac-specific, the longest diagnostic window time (Martins
et al., 1996), and the correlation is proximately proportional between peak values and the
infarct size (Licka et al., 2002; Panteghini et al., 2002). Therefore, the evaluations of
cardiac troponins have been crucial in cardiospecific diagnosis, risk stratification,
prognostic risk assessment, and therapeutic choices (Babuin and Jaffe, 2005; Newby et
al., 2003). Meanwhile, the reliability of troponins for diagnosing ACS has been
constantly questioned as well, because of the false positive troponin level caused by other
clinical situation instead of ACS, such like sepsis, renal failure, hypovolemia (severe
blood loss) , and etc(Jeremias and Gibson, 2005; Yang and Zhou, 2006), which will need
further investigation about the releasing mechanism.

1.2.1.4

Heart-type Fatty Acid Binding Protein (H-FABP)

Heart-type fatty acid binding protein (H-FABP) shares substantial similarity to
myoglobin. In releasing kinetics (Table 1.1) perspective, the low molecular weight (15
kDa) makes H-FABP possible to release rapidly into the blood stream circulation right
after (1 hour or so) myocardial infarction (Glatz et al., 2002). In terms of specificity and
sensitivity of AMI diagnosis, plasma H-FABP has been proved to be more effective over
myoglobin and equivalent potential in exclusion diagnosis (Chan et al., 2004; Pelsers et
al., 2005). Furthermore, HFABP is expected to replace myoglobin to become a clinical
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routine due to its performance in clinical application such as minor myocardial injury
detection of heart failure and unstable angina, infarct size estimation, the success or
failure of coronary reperfusion in AMI patients, and in-time detection of post-surgery
myocardial tissue monitoring, especially patients through coronary bypass operation
(Pelsers et al., 2005; Yang and Zhou, 2006).

1.2.1.5

C - reactive Protein

C-reactive protein (CRP) is an acute phase protein reactant, the release of which is
corresponding to acute injury, infection, or inflammation stimuli, like hypersensitivity
causes, inflammatory disease allograft rejection, necrosis, trauma, and malignancy. The
elevated CRP could demonstrate inflammation instead of erythrocyte sedimentation rate,
and respond to hormone change caused by pregnancy (Du Clos, 2000).

The

measurement of CRP at the hospital admission can be an independent predictor for
diagnosing lately coronary events; AMI and mortality caused by ischemic heart disease
were included as well (Liuzzo et al., 1994). Troponin and CRP can provide relatively
effective treatment suggestion for patients with unstable angina and non-Q–wave AMI;
the statistics indicated that the risk is only 1% for that patient presenting negative or
ultralow levels of CRP died in 14 days. In contrast, for elevated CRP level over than 15
mg/L, the risk will increase up to 9% and remain the same in the following periods. Even
though, it is still lack of consensuses in the right time to take CRP measurement and the
CRP potential in emergency department(Liuzzo et al., 1994).

1.2.1.6

B-type Natriuretic Peptides (BNP) and NT-proBNP

Natriuretic peptides are small signal chain proteins, presenting in the cell of the
cardiovascular system, including brain, heart and blood vessels. There are three types of
natriuretic peptides: A, B, and C natriuretic peptides. B-type natriuretic peptide (BNP) is
mainly synthesized in ventricular myocardium or arterial.
There have been fact proved that myocardial ischemia would cause BNP and NT-proBNP
released into the blood stream circulation (Wu, 2005).
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According to the American and European Cardiological Societies, the latest guidelines
regarded that BNP is a valuable serum marker for diagnosing heart failure. De Lemos
highlighted the prognostic value (de Lemos et al., 2001; Hunt et al., 2001; Remme et al.,
2001). Even though, the clearance characteristics do not reach the agreement, the clinical
data trials (FAST, GUSTO IV, and FRISC II) have strongly revealed the connection
between patients’ death with unstable coronary artery disease and the NT-proBNP level
(Jernberg et al., 2004). Since both BNP and NT-proBNP have demonstrate clearly that
their clinical value is precious in diagnosing and taking care of cardiac disease, BNP and
NT-proBNP elevation testing should be added in the menu of clinical practice routine
(Penney, 2005; Pfister and Schneider, 2004; Sluss, 2006).

1.2.2 Clinical application of cardiac biomarkers
The detection of cardiac markers elevated level is the fundamental procedure for patient
with suspect ACS, which is critical for the following medical intervention such as
assessment, diagnosis, risk stratification, status monitoring, decision making and
prognosis. Generally, to rule in the AMI or a certain type of ACS, it may take the
combination of various cardiac biomarkers; while, to rule out the AMI, one biomarker
test present negative might be enough. For example, cTnT and cTnI have been the
surrogates for cardiac necrosis: the data showed that cTnT and cTnI are the most
convincing indicators of myocardial cell damage among all the current available cardiac
biomarkers (Alpert et al., 2000). On the other hand, all the cardiac markers of various
processes of the acute coronary syndromes are useful as well. For example, one of the
common physiologic syndromes of ACS is plaque instability or disruption and platelet
activation, the marker (still under investigation) corresponding to plaque stability will
indicate such interruption.

C-reactive protein, as discussed before, is the foremost

biomarker demonstrating inflammation for assessment for quite long period risk
evaluation along with auxiliary reference of ACS (Christenson and Azzazy, 1998).
Cardiac ischemia and unstable angina are the initial physiologic process of ACS;
therefore, the marker such as H-FABP would also be engaged in clinical evolution. Since
the characteristics and releasing kinetics of troponin, CK-MB, and myoglobin have been
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well established(Alpert et al., 2000; Christenson and Azzazy, 1998; Christenson et al.,
2001), they are currently the core of clinical detection subjects.

Table 1.1: Clinical utilized cardiac biomarkers for diagnosing CVD. Adapted from
(Mohammed and Desmulliez, 2011)
Cardiac
biomarker

Clinical cut-off
levels

Clinical cutoff (h)

Peak
elevation (h)

Duration

CVD indicator type

Troponin I

0.01-0.1 ng ml-1

4-6

18-24

4-7 days

Detection of MI and tool for
risk stratification

Troponin T

0.05-0.1ng ml-1

3-4

18-24

10-14
days

Detection of MI and tool for
risk stratification

Myoglobin

70-200 ng ml-1

1-3

6-12

12-24 h

Early detection of MI and
reperfusion

CK-MB mass
assay

10 U L-1

3-4

12-24

24-36 h

Early detection of MI

H-FABP

6 ng ml-1

1-3

6-8

24-36 h

Early detection of MI

C-Reactive
Protein

CVD inflammatory
No definitive or clinical consensus

NT-proBNP

1.3

Ventricular overload or
ischemia or necrosis

Objective and outline of thesis

The ultimate goal of this project is to develop a compact multiplex cardiac condition
diagnostic panel for point-of-care testing based on electrochemical immunoassay
technology. As discussed before, the combination of myoglobin, CK-MB and troponin I
will help diagnose the exact stage of myocardial infarction; while the grouping of HFABP, CRP and Troponin will define the certain type of cardiac condition, and more. As
the first step of the whole project, we developed a highly sensitive immunosensor for
Troponin I and investigated the related experimental condition. So, this dissertation is
comprised of six chapters in the following orders:
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Chapter 1, background introduction, covers the information of cardiovascular disease
diagnostic and clinically utilized cardiac biomarkers. The research motivation, objective
and outline are also presented.
Chapter 2, literature review, provides a review on the current situation of point-of-care
diagnostics, update the study of nanomaterial-based electrochemical immunosensor, and
present technology for cardiac biomarker detection from laboratory and clinical
perspective.
Chapter 3, sensor fabrication and bio-detection, presents the principle and procedure of
immunosensor fabrication and configuration. Photolithography in cleanroom using the
lift-off technique, e-beam metallization, and sandwich enzyme-linked immunosorbent
assay are described in detail.
Chapter 4, electrode modification, describes the electrochemistry of the biosensor
enhanced by three nanomaterials, carbon nanotube, golden nanoparticle, and chitosan. As
a promoter for signal amplification and electro transferring, the response signals of three
nanomaterials biosensor are investigated and discussed.
Chapter 5, enzyme label and substrate comparison study and system optimization,
compares the activities of two commonly used enzyme label, HRP (horseradish
peroxidase) and ALP (Alkaline phosphatase) in different substrates. A concept of
developing GOD biosensor and cTnI immunosensor, also the feasibility is investigated.

Chapter 6, conclusion and outlook, summarizes all the chapters of the thesis and
emphasizes the contribution of this research project. Also, a few recommendations for
future research have been addressed.
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Chapter 2
2

Literature review

This chapter reviews the current status of point-of-care (POC) immunoassay testing,
advanced nanomaterial technology for biosensor application, and up-to-date development
of cardiac biomarker detection. The core of this project is to develop high-performance
cardiac biomarker transducer for POC application based on electrochemical enzymelinked immunosorbent assay (ELISA); thus, the review includes discussion of clinical
application of innovative biosensor, the prospects and challenges in terms of point-ofcare cardiac condition diagnostics.

2.1

Point-of-care immunoassay

Diagnostics is indispensable in health care for both developed word and the developing
world. Accurate diagnostics can provide proper and timely care to patient, guarantee the
safety of blood banking, surveil emergency public health intervention and evaluate longterm health strategies (Sluss, 2006; Yager et al., 2008). Nowadays, clinical diagnostics
heads towards two opposite directions: consolidation and automation of testing in
centralized laboratories (Blick, 1999) and near patient testing in decentralized format (StLouis, 2000). Even though, the cost and the time involving have been reduced
tremendously (Blick, 1999); in poor setting environment, the laboratories are not only
hindered by physical constrains (including limited power supply, inconsistent
refrigeration status, and poor water quality), but also be challenged by the following
factors (Ridderhof et al., 2007; Stedtfeld et al., 2012):


Laboratory facilities and capacities vary among countries and within one country



Irregularly laboratory quality and management control



Deficient fundamental equipment and unreliable experiment supplies



Shortage of proficient personnel and restricted training occasions

Therefore, under the lack of financial and technical support circumstance, point-of-care
(POC) platform has more significant utility potential for performing diagnostic due to its
merits in clinical application over traditional lab-based procedures. For example, timely
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diagnostic information provided by POC testing ensures the correct and proper treatment,
shorten the duration of hospitalization and improve the quality of patient cares (Birkhahn
et al., 2011). (Figure 2.1)

Figure 2.1: Central laboratories testing versus point-of-care testing in the clinical
situation.
Generally, the definition of POCT is the testing performed near by the patients (St-Louis,
2000; von Lode, 2005), the performing location of which includes primary care facilities,
hospital units, emergency department, mobile nursing practices, homes even peculiar
situation like military or space shuttles etc. (von Lode, 2005). Even if the first rapid and
easy-to-use immunoassay technology was realized by the pregnancy test over 43 years
ago (Cabrera, 1969), the majority of present POCT applies to non-immunoassay analytes,
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say glucose measurement. The perfection of POC technology allowed the immunoassay
POCT for rapid growth within the last two decades.
In 2004, the World Health Organization (WHO) proposed an elemental guideline for the
desirable POC device in less-developed areas, addressing from the cost, accuracy and
feasibility perspective: (Mabey et al., 2004)


Affordable for the high risk group and equipment-free



Sensitivity (minimal falsely positive)



Specificity (minimal falsely negative)



User- Friendly (easy to operate and requiring little training program)



Rapid (to ensure proper treatment at the initial visit) and robust



Delivered to those who need it

However, for individual clinical applications, there are detailed, thorough, extensive and
extraordinary requirements and specifications. The analytical performance requirements
manifest two characteristics: practicability (as sample type, turn-around times, and
operating skills) and reliability (e.g., limit of detection, interference, precision, accuracy,
linearity and the measurement range) (Fraser, 2001). Differing from laboratory testing
procedures, the main focus is on the practicability characteristic since the tests performed
by unskilled personnel. Nevertheless, the accuracy of POCT is critical due to the closely
connection to medical decision. In principle, the basic imprecision of a methodology
cannot exceed fifteen percent for crucial treatment decision (Alpert et al., 2001).
Actually, the diagnostic situation in the physician’s offices in a developed country is
correspondent with the method utilized in limited resource environment. Under both
circumstance, lateral-flow immunochromatographic immunoassay strip test is the
absolutely dominant format, regardless of the low sensitivity levels (around 70%). In
higher-income countries, the physician chose “simple” test over highly complicated but
precise diagnostic based on clinical and social consideration: on the one hand, short turnaround times (TATs) about 15 to 20 min is desirable for timely medical decision; on the
other hand, for the regulation of quality-control, only certain performing testts are
approved by the Recommendations for Clinical Laboratory Improvement Amendments of
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1988. The US Food and Drug Administration (FDA) describes the certain testing method
“simple” with an “insignificant risk of an erroneous result.”
According to the FDA, an ideal patient onsite diagnostic should have the following
features: (Yager et al., 2008)


Completely automated instrument or unitized, self-packed testing



Utilize unprocessed specimens or capillary blood, nasal swabs, or urine



No sophisticated operation requirement



No intervention between analysis steps



No equipment maintenance, calibration, interpretation or calculations



No results analysis including data interpretation

With all the guidelines and regulations, POC immunotesting not only provides a
multimillion dollars market but also is the fast growth part in the in-vitro diagnostics
(IVD) business (Rosen S, 2004). Since then, great amounts of improvement in
developing POC diagnostic platforms have been accomplished for both automated and
manual approaches, which boost the introduction of POC diagnostic into the developing
world.
Conventional straightforward manual assay has three primary assay formats, including
agglutination assays, microscopy for direct detection of the analyte, and lateral flow tests
(rapid diagnostic tests or RDTs) for detecting pathogen specific antigen or antibodies.
(Figure 2.2) Even though the well-done performance of these tests can benefit both
patients and health care resource, the quality will be considerably compromised by the
poor source environmental setting. For instance, to a great extent, the accuracy of
microscopes is influenced by high quality supplies, skilled staff, and the data
interpretation. To solve this problem, scientists and researchers put enormous effort in
investigating disease pathogenesis at a molecular level along with biomarker discovery
and identification. The distinct benefits brought by molecular diagnostics (for example
microfluidic technology and nanostructures sensing) can be summarized as: portability,
the possible lowest detection limits, sensitivity improvement, and parallel recognition for
multiplexing approach and etc. (Nam et al., 2004; Nam et al., 2003). All the benefits
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coupled with small sample volumes contribute to a rising impact of micro-diagnostic
technology in both the clinical and academic department.
Even though, great amount of papers published regarding POC device research, the POC
device integrated using daily media (e.g mobile phones, mp4, and cameras) and paperbased microfluidic are the most creative and attractive for the widespread application.
Stedtfeld et al. successfully developed genetic fluorescent microfluidic chip, called GeneZ, for rapid quantitative detection of various biomarkers. This fully automated design
featured in low cost, easy-to-operate, high sensitivity and specificity. The prototype
(Figure 2.3) was connected with an iPod Touch for data reception and analysis, and then
reported the result through Wi-Fi immediately.(Stedtfeld et al., 2012)

Figure 2.2: Schematics of typical POC testing. (a) An agglutination for HIV serology
test. (b) Steps in rapid diagnostic test (lateral-flow test) for malaria antigen
detection. (c) Classic light microscopy using Giemsa stain, results shown in both the
thick and the thin smear. Figures adapted from Ref (Buhrer-Sekula et al., 2003;
Kemp et al., 1988; Payne, 1988)
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In addition, adding the attractiveness, Liu et al. and Ge et al. reported a three-dimensional
paper microfluidic device based on origami principle. Liu et al. (Liu and Crooks, 2011)
reported using classic lithography to create channels and reservoirs based on origami
principle. (Figure 2.4(a)) Ge et al. (Ge et al., 2012) developed sandwich-type
chemiluminescence immunosensor integrating with blood separation, automated rinsing
and parallel immunoassay. For integrating ELISA with paper-based micro-sensor, Zang
and Cheng approached in a different perspective. Zang et al (Zang et al., 2012) designed
two pieces of paper, one fabricated with electrode pattern, the other immobilized with
nanomaterials and antibody, and then overlapping to assemble the sensor. (Figure 2.4
(b))Cheng et al. (Cheng et al., 2010) fabricate the 96-microzone plate on paper for ELISA
detection, high sensitivity, high specificity and less complexity(Figure 2.4 (c)). Lately,
Delaney et al. (Delaney et al., 2011) constructed electrochemiluminescence detection on
paper microfluidics utilizing cell phone camera for chemiluminescence emission. (Figure
2.5)

Figure 2.3: Gene-Z schematics and prototype. (a) An empty chip with four parallel
reaction arrays. (b) Working principle and decomposition structure of the Gene-Z
chip (c) Gene-Z prototype operated by an iPod set on the recharge port and the chip
insertion door. Figures reprinted from Ref (Stedtfeld et al., 2012)
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Figure 2.4: Schematics of various paper-based devices. Adapter from Ref (Zang, Ge
et al., 2012; Cheng, Martinez et al., 2010; Ge, Wang et al., 2012)

Figure 2.5: Schematics of paper-based microfluidic electrochemiluminescence:
fabrication and analysis. Figure adapted from Ref (Delaney et al., 2011)
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2.2

Immunosensor and nanomaterial enhancement

The device designed to qualify or quantify a certain biochemical molecule, say DNA
sequence or protein molecule, is defined as biosensor. One of the most popular format
biosensor is affinity-based biosensor, standing for using an immobilized capture probe to
selectively bind the target molecule or analyte, the antigen in our case. Instead of sensing
certain molecule in solution, affinity-based biosensor transfers the difficulty into
detection a variation on the localized surface, which can be read out in various ways.
Based on the detection methodology, the biosensor can be classified into optical,
electrochemical, magnetical, and mass-loading immunosensor. (Bakker, 2004; Daniels
and Pourmand, 2007; Drummond et al., 2003; Thevenot et al., 2001)

2.2.1 Nanomaterials: classification and application
The measureable size is less than 100 nm in any dimension; then this material can be
defined as nanostructure. Based on the various dimensions, the materials can be divided
into zero- (0D), one- (1D), and two-(2D) dimensional nanomaterials. Since we utilized
zero- (0D), one- (1D), and two-(2D) dimensional nanomaterials in the electrodes surfaces
modification, more details about zero- (0D), one- (1D), dimensional nanomaterials will
be discussed later. Generally, in a diagnostic sensor requires one or multiple receptors for
binding analytes along with signal generation function group, saying, a detectable label in
the reacting event. The function of nanostructures in the molecules reaction can be
varying with the physical, mechanical, or chemical properties.

As a label of any

biomolecules, it requires that the nanomaterials to meet these following criterias: stable in
the corresponding buffer or fluids, detectable in the existence of required circumstance,
and capable of conjugating the molecules with the functional groups. To achieve this
objective, the surface usually is functionalized with ligands before spreading the
dispersion of the nanoparticles aqueous on. As shown in Figure 2.6 illustrates the mainly
applied nanostructures in the diagnostic assay device or technology development. In
addation, a review about the properties, application and detection principles of the
nanostructures are addressed as follows (Kurkina and Balasubramanian, 2012).
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Figure 2.6: An overview of various nanostructures (NSs) that are used in diagnostic
assays. Reproduced from Ref. (Kurkina and Balasubramanian, 2012)

2.2.1.1

0D nanostructures

As shown in Figure 2.6 -0D, the sizes of three dimensions are all less than 100 nm, then
the materials are called as 0D nanostructure. A few classic representatives as shown in
Figure 2.6-0D, includes nanoparticles and nanospheres, which can be divided into
magnetic, metallic, semiconducting, or insulating

nanoparticles based on the

conductivity, saying, electrical properties. The basic function of nanoparticles can be
essentially summarized as follows: immobilizing the biomolecules on certain surface,
catalyzing electrochemical reaction, enhancing electron transferring, acting as a reactant
or labelling biomolecules for further experiments, and etc.(Luo et al., 2006).
Speaking of nanoparticles for immobilizing biomolecules, gold nanoparticles (AuNPs),
one of the most frequently used nanoparticles, can be utilized for both immobilization
promoter and labels reactor in electrochemical immunosensing platforms, which has
illustrating distinguish results in enhancing the signal response, lowering the detection
limits in enzyme-based electrochemical biosensors, immunosensors, and DNA
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hybridization detection (Kerman et al., 2008; Liu and Lin, 2007). AuNPs can be strongly
attached to electrode surfaces through self assembled monolayer (SAM) of alkanethiol
molecules due to the firm S–Au bonding, which creates plenty area for immobilizing
biomolecules proximate to the surface of electrodes or biosensors (D'Orazio, 2011;
Merkoci, 2007).

2.2.1.2

1D nanostructures

As shown in Figure 2.6––1D, 1D nanostructures stand for the size of these materials less
than 100 nm in two dimensions, which can be considered as elongated version of
nanoparticles, saying, tubes. Carbon nanotubes (CNTs), nanopores, nanowires and
waveguides are all considered as 1D nanostructure.
Carbon nanotubes (CNTs), formed by rolling a thin layer of graphite to cylindrical
structure, has the unique electrical properties such like metallic, semiconducting or
superconducting electron transporting capability. CNTs, either single-wall carbon
nanotubes (SWCNT) or multi-wall carbon nanotubes (MWCNT), can be produced in
various synthesis ways, namely, chemical vapour deposition, laser evaporation, or carbon
arc methods and most commercially available CNTs are in powder form (Kurkina and
Balasubramanian, 2012). The average diameter of SWCNT is approximately 1 nm
leading to high surface-to-volume ratio of such materials.

Therefore, the unique

electrical properties such like resistance display extremely high sensitivity in responding
to the environmental changes in terms of chemical or biological variables. Furthermore,
high surface-to-volume ratio and the indefinite conductivity contributes one of the most
prevalent applications of CNTs to being the functional supporters electrical detectors in
the label-free heterogeneous assays (Balasubramanian and Burghard, 2006; Kurkina and
Balasubramanian, 2012; Wanekaya et al., 2006). Furthermore, CNTs can play a role in
being utilized as optical labels, such like characterizing Raman signal, and being a carrier
of payload labels (Duan and Lieber, 2000) such like the case of silica nanospheres
(Kurkina and Balasubramanian, 2012).
Another extraordinary advantages of CNTs are acting as an immobilization matrix for
biosensors, either biocatalytic or affinity biosensors, which are owing to the existence of
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reactive groups on the surface, fast electron transfer kinetics (particularly beneficial for
electrochemical biosensors) and the high surface to volume ratio (D'Orazio, 2011; Rivas
et al., 2007).
The application of CNTs can enhance electron transferring of electrochemical biosensors,
because the electron communication between immobilized proteins, mediators will lead
to strong and sound signal response and lower the case of overpotentials to overcome the
corresponding inference, which has been reported in the amperometric glucose biosensor
applications (more discussion is in Chapter 5). Furthermore, the value of CNTs in
electrochemical biosensor can also display by promoting sensitivity, shortening the assay
time and elevating the clinical or analytical performance in terms of stability and
precision and etc.(Justino et al., 2010).

2.2.2 State-of-the-art nanomaterials for cardiac immunosensors
Numerous literature manifest the benefit of utilizing nanotechnology in biosensors, for
instance the ultrasensitive detection of cardiac biomarkers can be tremendous helping in
provide accurate and timely information of diagnosis of acute myocardial infarction.
Meanwhile, the present biomarker study has explored to unstable angina, coronary plaque
and other types of cardiac disorder conditions. Lin’s group has successfully developed
deluxe cardiac biomarkers array of the nanostructure in the form of nanowells which
were formed by biogenic nanoporous silica on the top of gold electrode. The silica was
derived from Coscinodiscus wailesii, the eukaryotic unicellular photosynthetic algae, and
then was overlayed on the top of gold substrate to form the structure of nanowells for
detecting C-reactive protein (CRP) and myeloperoxidase (MPO), both of which are
highly relevant to risk of coronary plaque rupture. The general diameter of each
nanowell is 40 nm with a bottom of gold substrate electrode. The protein detection was
implemented by quantifying the immunoreaction, namely the interaction between
antibody and antigen, the affinity of which will disturb the regular charge distribution of
the interface of the electrode and liquid. The shifted resistance can be measured by
impedance spectroscopy and is proportional to the concentration of CRP and MPO.
Compare to planar gold electrodes, the signal was cumulated and enhanced by the
nanowells nanostructure with an exceedingly low limit of detection 10 pg mL-1 of CRP
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and MPO in serum samples(Lin et al., 2010c). Chua et al succeeded in developing a real
time, label-free, highly sensitive human cardiac troponin-T (cTnT) electrochemical
immunosensor (Figure 2.7) by fabrication of oriented silicon nanowires (SiNW) clusters.
The immunosensor utilizes the properties of complementary metal-oxide semiconductor
(CMOS) and field effect transistor-compatible detection principle to characterize cTnT
both in buffer solution or undiluted serum. The anti-cTnI antibody was immobilized on
the functionalized nanowires on the surface, the conductivity of which will increase along
with the amount of cTnT antigen binding to the antibody. This phenomena was based on
the n-type semiconductor characterizations, namely, the impurity will results in free
electron then increase the conductivity. The cTnT level can be detected as low as 30 fg
mL-1 in undiluted serum and 1 fg mL-1 in buffer dilutes (Chua et al., 2009).

Figure 2.7: SiNW device demonstration: (a) SiNW microfluidics chip; (b) the layout
of the SiNW device array; (c) SEM image of nanowires clusters. Adapted from
(Chua et al., 2009).
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The significance of CRP has been realized recently. Many literature published various
novel CRP detection immunosensors for clinical application. An acoustic, highly
sensitive immunosensor for the detection of CRP was presented by McBride JD, which
testified the competitive sensitivity of CRP sandwich ELISA assay by the Resonant
Acoustic Profiling (RAP™) biosensor (Akubio Ltd., Cambridge, UK). Applying a high
frequency voltage on the piezoelectric crystal, it will induce oscillation and be monitoring
the resonance frequency instantly. The immunosensor was operated on two different
modes, direct and sandwich, on which the antibody along with the corresponding antigen
bonded to the reading crystal by classic covalent bond and on the other crystal IgG
immobilized as the control set to eliminate background signal. The specific binding
reaction, immunoreaction between antibody and antigen, on the testing crystal will lead
to a reduction of the frequency of the oscillation. The serum CRP detection limit of such
immunosensor is 13 ng mL-1 of the direct mode and 3 ng mL-1 of the sandwich type,
respectively. According to the statement of this literature, this immunosensor has
immense potential for clinical application as the monitor for prediagnosis of
cardiovascular disease, since the CRP assay requires the maximum low detection limit is
300 ng mL-1 (McBride JD, 2008).
Meanwhile, cardiac troponin-I (cTnI) remains the most popular biomarkers study
projects. Both Wei’s group and Masson’s group developed a cTnI immunosensor based
on s surface plasmon resonance technology. Wei et al can monitor the real time action of
several and constant monoclonal antibodies and antigen cTnI, such as association,
dissociation and affinity. The experimental system was build on a gold SPR chip for
sandwich ELISA detection, and the optimized system has a low detection limit of 0.25 ng
mL-1, which is less than almost 90% of that of the direct SPR assay (Wei et al., 2003).
Even though, the sensitivity of this immunosensor can be satisfy the practical standard for
detecting sera cTnI from patients with suspect AMI. Still, the shortcoming of this
immunosensor is low sensitivity and long processing time. Namely, nonspecific protein
adsorption causing low sensitivity which can be solved by washing after each incubation,
which calls for 40 minutes for the assay. Masson et al. tried to solve the same problem in
their research. They used a self assembled monolayer, which is comprised of Nhydroxysuccinimide activated 16-mercaptohexadecanoic acid, to remove the nonspecific
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binding responding of the serum protein for cTnI immunosensor utlizing SPR
technology. However, it still needs more optimization or improvements before the
application of AMI diagnosing since the detection limit is 0.7 ng mL-1 in undiluted serum
in direct mode of immunoassay.
As discussed before, gold nanoparticles (AuNPs) show appreciable enhancement in
fluorescence based biosensor. Hong and Kang reported a fiber optic based cTnI
immunosensor by establishing- a self assembled monolayer through nanoparticles
immobilization at a mediate distance from fluorophore. The immunosensor based on the
sandwich type immunosensing using a second antibody labelled with a fluorescence
enzyme. Because of the existence of AuNP, the quantitation of cTnI with a fairly low
detection limit, down to several picomolar concentration (approximately 0.2 ng mL-1). It
can be explained by that free or self-quenching electron was attracted by AuNP and
transfer to working zone, surface Plasmon polariton filed, and then the signal was
significantly improved. This immunosensor still needs the washing steps to remove the
nonspecific binding, which is the similar case with most optical based immunosensor
(Hong and Kang, 2006).

2.3

Current commercialized cardiac point-of-care assays

The POCT devices for cardiac biomarkers are fundamentally based on immunoassay
detection methods. A general principle of measuring various kinds of analytes using
antibodies can be summarized in the following prospects: antibody binding to the analyte
or antibody-antigen connection, isolation antibody-antigen complexes from excess
regents or antibodies for the signal measuring, and calibration the corresponding
relationship between signal response and the mass of analyte-antibody to establish
standard curve. Currently, the commercialized cardiac POCT devices for clinical
utilization can be divided into three categories: lateral–flow technology (LFT), flowthrough immunoassay device, and sandwich immunometric methods (Sluss, 2006).
Among all the analytes of POC immunotesing, the immunoassay for cardiac biomarkers,
troponins in particular, grows the fastest, with an approximately 15-20% annual growth
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(von Lode, 2005). In the current market, the qualitative and quantitative POCT devices
are successfully commercialized for myoglobin, CK-MB, cTnT, and cTnI, as shown in
Table 2.1.
All the assays shown in Table 2.1 are utilizing whole blood or anti-coagulated plasma
within 20 minutes to generating results, which is portable, convenient, and rapid
(Christenson and Azzazy, 2009; Di Serio et al., 2006; Kost and Tran, 2005; LeeLewandrowski et al., 2003; Storrow and Gibler, 1999). Comparing to qualitative testing,
under the guidance from NACB POC, test results in quantitative ways offer unique
power in risk stratification and ultralow sensitivity (Morrow, 2004; Pham et al., 2004).
The 2-site antibody immunometric assays, also called sandwich immunometric assays,
are suitable for highly specific protein level measurement, which is the dominant
technology in measuring biomarkers in multimarkers assays, fully-automated and
centralized laboratory instruments. Therefore, sandwich type immunoassay is the leading
format of the detection method of the cardiac markers since they process various
independent antigenic epitopes. Comparing to single antibody immunoassays, one of the
most merits of the 2-site antibody immunometric assays are the degree of analyte
specificity achieved by targeting 2 antigenic sites then along with high accuracy and
precision of the test results. Miniaturization is the current trend for both centralized
laboratory analysis and decentralized POC device (POCT device). A few POCT devices
for cardiac detection are depicted in detail as follows.
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Table 2.1: Current Cardiac point-of-care available device. Adapted from
(Christenson and Azzazy, 1998)
Device

Cardiac
marker

Suggested cut-off

Roche cardiac T®
rapid assay

cTnT

0.1 ng mL-1*

CK-MB

5 ng mL-1
(Abbott method)

Myoglobin

50 ng mL-1 (Behring
Diagnostics method)

Nanogen cardiac
STATusTM panel

cTnl
CK-MB
Stratus® CS
STAT
fluorometric
analyzer (Dade
Behring Inc)
Triage® cardiac
panel (Biosite
Diagnostics)

Male: 98 ng mL-1
Female: 56 ng mL-1

cTnl

0.06 ng mL-1

CK-MB

10.0 ng mL-1

Myoglobin

170.0 ng mL-1

cTnl

1.0 ng mL-1
LLD 2.4 ng mL-1
(range 0~400 ng mL1
)
LLD 0.32 ng mL-1
(range 0-80 ng mL-1)
LLD 0.03 ng mL-1
(range 0-32 ng mL-1)
0.08 ng mL-1
(reportable range: 050 ng mL-1)

CK-MB
cTnl

iSTAT (Abbott
Diagnostics)

cTnl

Assay Time
(min)

Specimen (type and volume)

12

150 μL heparin whole blood

Aid in the
diagnosis of
cardiac
ischemia

15

200 μL serum or heparinized
whole blood or plasma

All makers: Aid
in the diagnosis
of AMI
cTnl: Risk
stratification

14 min to the
first result, 4
min for each
additional
result

Whole blood (lithium or sodium
heparin): 3 mL-1
Plasma (lithium or sodium
heparin): 200 μL for the first test,
100 μL for each additional test

Aid in the
diagnosis of MI

~15

250 μL heparinized whole blood
or plasma

Aid in diagnosis
of AMI

~15

Heparinized whole blood or
plasma

Help diagnose
AMI

~10

16 μL whole blood

1.5 ng mL-1 (Dade
Stratus method)
3.5 ng mL-1

Myoglobin

Myoglobin
Response
biomedical
corporation

Manufacture’s
claim
Myocardial
damage is
detected

* TnT values indicating: <0.05 ng mL-1, negative; between 0.05 to <0.1 ng mL-1, low and repeat
testing within one hour with freshly collected blood; between 0.1 and 2.0 ng mL-1, myocardial
damage; >2.0 ng mL-1, massive myocardial damage.
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2.3.1.1

Cardiac STATus™ device (Nanogen Inc., San Diego, CA)

The STATus™ assay system based on the principle of immunochromatographic solidphase immunoassay; therefore, it can only provide the semi-quantitative results. For the
accurate or precise reading of cTnI or CK-MB, it has a different device also
commercially available. As shown in Figure 2.8, the testing panel includes myoglobin,
CK-MB mass, and cTnI and the results were read and processed by LifeSign DXpress™
Reader. The device can be suitable for whole blood (heparinized), plasma or serum. The
principle of the working schematics has shown in Figure 2.8 as well, which is the classic
pregnancy testing style. After the sample was dispensed into the entrance well and was
driven by the diffusion force to the testing zone. The sample was first mixed with the
mouse monoclonal antibodies with a colour label and the complex react with the second
antibody conjugated with a biotin. Then the sandwich complex flow through the display
zone to react with the streptavidin, then the LifeSign DXpress™Reader can convert the
intensity to a concentration (Christenson and Azzazy, 2009; Sluss, 2006).

Figure 2.8: Cardiac STATus™ Kit- Triple markers testing. Adapted with
permission from Nanogen Inc.
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2.3.1.2

Stratus® CS STAT fluorometric analyzer (Siemens Medical
Diagnostics, Glasgow, DE)

The Stratus CS (Figure 2.9) bases on sandwich immunoassay technology and
fluorometric detection technology provides quantitative results of CK-MB, myoglobin,
and cTnI, which can be suited for lithium heparin whole blood or plasma. The whole
blood was processed first, centrifuging on-board to separate the blood cells from the
plasma, and then the plasma was driven by centrifuge force to the capture antibody which
were immobilized on a solid-phase glass fibre matrix. Like the i-STAT system, (details
in section 2.3.1.6), then the second antibody conjugated with alkaline phosphatase reacts
with the antigen to form a sandwich complex. To remove the nonspecific binding, the
instrument followed by adding the washing buffer and clean the sample matrix, at the
same time, there is a substrate can by catalyzed by alkaline phosphatase to generate a
fluorescent signal which is proportional to the exist amount of myoglobin, cTnI and CKMB (Christenson and Azzazy, 2009; Sluss, 2006).

Figure 2.9: Stratus® CS STAT fluorometric analyzer. Reprinted with permission
from Siemens Medical Diagnostics.
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2.3.1.3

Triage® system for cardiac marker measurement (Biosite
Diagnostics Inc., San Diego, CA)

The Triage® Cardiac system (Figure 2.10), based on microfluidics structure and
immuno-fluorescence technology, has two basic components for detection triple cardiac
markers at one reading, a cartridge containing all the structure and reagents and the data
analyzer, the Triage® meter. The whole blood with anti-coagulation and plasma can be
applied on the cartridge. When the sample enter the port, the blood cells were removed
by filtration and the plasma flows through to the reaction well and reaction with the
detection antibody labelled by fluorescent enzyme. When the complex (detection
antibody- antigen) flows through the whole cartridge, the corresponding antibody can
capture the specific complex, in this case are myoglobin, CK-MB, and cTnI, will “grab
their owns complex” complex. Therefore, the three sandwich complexes were located in
different zones, and detected by the Triage meter to get the fluorescent signal response
(Christenson and Azzazy, 2009; Sluss, 2006).

Figure 2.10: Biosite’s Triage flow-through detection technology. Reprinted with
permission from Biosite.
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2.3.1.4

RAMP™ cardiac marker testing (Response Biomedical
Inc., Burnaby, B.C., Canada)

RAMP stands for the Rapid Analyte Measurement Platform (RAMP) (Figure 2.11) is
based on quantitative immunochromatographic assay for cTnI and CK-MB detection.
EDTA whole blood is the only specimen for this immunosensor, and must be combine
with buffer to dilute before enter the analyzer. The analyzer contains capture and
detection antibody is both monoclonal, indication this device has lightly robust but strong
sensitivity.

Like the rest of cardiac detecting devices, the antigen combining with

detection antibody and the complex react with the capture antibody. Partial fluorescentlabelled latex particles were coated on the detection antibody to generate signal response
in the working zone. The excess fluorescent-labelled were moved and immobilized in the
other zone as the blank experiment. Then two working zones have been detected by the
RAMP Clinical Reader, the differences between the two values are used to calculate the
concentration of each analyte (Christenson and Azzazy, 2009; Sluss, 2006).

Figure 2.11: RAMP cardiac marker system. Reprinted with permission from
Response Biomedical Corporation.
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2.3.1.5

STAT® system cardiac Troponin I (Abbott Point of Care
Inc., East Windsor, NJ)

CTnI test cartridge of i-STAT (Figure 2.12) is based on classic sandwich ELISA
detection method, which can be utilized for whole blood (either lithium or sodium
heparinized), plasma or non-anticoagulated whole blood (freshly drawn blood samples
with any anticoagulated treatment). Because the cartridge itself contains all necessary and
sufficient reagent to dilute, capture, wash or conjugate the blood sample; however, for the
freshly drawn blood, it requires to apply in the cartridge before the blood started to clot
(usually 1 minute). I-STAT cardiac system can also be called as a simultaneous detection
system, since the capture and detection antibody was forming as a complex at the same
time and the washing buffer also plays a role of detection substrates. The anti-cTnI
human antibody (monoclonal capture antibody) was immobilized on the silicon based
electrochemical sensor surface during the fabrication. A polyclonal second antibody is
firstly conjugated with alkaline phosphatase (ALP) and reacts with antigen (cTnI) when
the sample was added in the cartridge, since the conjugated detection antibody was
placed closed to the sample entry well. Then the complex of antigen-antibody-alkaline
phosphatase label was driven by capillary force and pneumatic pressure flowing through
within the cartridge to the surface of the electrochemical sensor coated with capture
antibody. Then a washing buffer remove all the unbinding enzyme conjugate, nonspecific binding, which is the biggest influence in the sandwich ELISA type
immunoassay. This washing buffer also contains liquid substrate which can be catalyzed
by alkaline phosphatase to generate an electrochemically detectable substrate and then
generate proportional response (current) to the amount of the cTnI within the sample,
which was processed by a hand-hold analyser to generate the critical analysis results.
The i-STAT cardiac marker detection system (cTnI in particular) has a low detection
limit of 0.02ng mL-1, and a relative narrow linear range between 1ng mL-1 to 50ng mL-1.
However, the design of the i-STAT is one of the most successful examples and the only
electrochemical based POCT cardiac device (Christenson and Azzazy, 2009; Sluss,
2006).
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Figure 2.12: i-STAT® system Portable cardiac analyzer and the explode view of the
cartridge. Reprinted with permission from Abbott Point of Care Inc.

2.3.1.6

Roche cardiac reader (Roche Diagnostics, Indianapolis)

The cartridge of Roche Cardiac Reader (Figure 2.13) is based sandwich type ELISA and
immunochromatography for measuring cTnT or myoglobin. EDTA whole blood or
plasma can be used in the cartridge.

The principle of Roche Cartridge has many

similarities with Biosite’s Triage. The blood cells were removed by filtration before the
reaction starts. Both the antibodies were solubilised by the sample: the capture antibody
was bound with biotin, and the detection antibody was bound with gold particles. The
complex flow to the streptavidin immobilized zone, detection zone, the gold-label
sandwich complex will concentrate to be visibly observed. The excess labelled antibody
will bind with anti- IgG as a control. Then the cartridge can read visibly for qualification
measurement or use cardiac reader analyzer for quantities measurement.
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Figure 2.13 : Roche Cardiac Reader system and principle schematic. Reprinted
with permission from Roche Diagnostics and Ref. (Collinson et al., 2001)

2.4

Summary

We have reviewed the update developments in diagnosing criteria and device innovation
in cardiovascular disease, AMI in particular. The proposed research information from
various laboratory groups not only offers critical research perspectives, but still many
challenges remain to be solved. The current commercialized available cardiac detection
kit, the majority of which is based on the optical detection methodology, can provide
results within 20 minutes near the patients with satisfying accuracy and sensitivity.
However, the apparatus for optical detection kit is expensive and hulking, which can not
realize portable then will not be suitable for frequently mobile circumstances. While,
comparing to the majority, i-STAT is the sole electrochemical based immunosensor with
excellent portability, but with narrow detection range (0 to 50 ng/ml) and less rebuts.
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Chapter 3
3

Sensor fabrication and biodetection

This chapter will present the principle and procedure of immunosensor fabrication and
configuration. A particular description includes photolithography in cleanroom using the
lift-off technique, e-beam metallization, and sandwich enzyme-linked immunosorbent
assay (ELISA).

3.1

Introduction

In the early 1990s, microfluidic technology was successfully developed and introduce to
the world, since then, countless attentions and efforts were poured into this novel and
promising technology. Particularly, to integrate immunoassay with microfluidic
technology to realize high specific antibody-antigen reaction comes with great benefits
along with substantial challenges. The on-chip devices can ameliorate the
immunosensing performance through the automated operation significantly in terms of
shortening the assay time, economising the consumption of reagents and sample,
improving the reliability and sensitivity, and coordinating parallel or sequential assays in
one platform (Bange et al., 2007; Kurita et al., 2006; Zaytseva et al., 2005). Basically,
the critical aspects to construct a microfluidic immunosensor include device
microfabrication, capture antibody (probe) immobilization, immunoreaction, and signal
detection scheme (Dong et al., 2007).
Lift-off and etching are the most common approach to fabricate metal or oxide
microstructures the surface of semiconductors. Lift-off performs as an additive process
during the microstructure fabrication, in contrast, the etching presents subtractive
process. During the etching process, firstly fabricate a metallic pattern directly coating on
the substrate with metal or oxide surface, followed by using photoresist to overlay the
desired pattern of the mask, and then, the etching process will remove the metal or oxide
which is not being covered by the photoresist, which can be classified as wet chemical
etching or dry etching. Wet chemical etching is the more popular in the etching process,
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but it will cause the isotropy of the whole process and or overcut/undercut the
photoresist. On the other hand, dry etching is an optional choice but requires
sophisticated and expensive machine to generate reactive ion plasma. The post-etching
process usually involves residue removing in a solvent bath (Golden et al., 2009).
During the lift-off process, it requires an inverse mask pattern to print a sacrificial
photoresist layer. The pattern of the substrate, metallic or oxide, is generated by blanked
coating by the photoresist and the sacrificial layer was washed off as well. Meanwhile,
the materials deposited on the top of the sacrificial layer was washed off which has been
indirectly contacted with the substrate surface. The lift-off technique can be classified
into many types, all of which will be suitable for metallization by e-beam and sputtering
techniques. But there are several defects will occur during the process, such as retention,
“tails”, “tears”, “flagging” or “fencing”, which is not quite relevant to the types of the
materials. Retention stands for the pattern of the substrate showing undesired and residue
metal pattern, which might be caused by the insufficient lifting time or solution resulting
in the excess metal left on the substrate. The circumstances mostly happened when the
metal coved the photoresist thoroughly and without any gaps during the metal deposition
during the photoresist being penetrated and dissolved by the solvent. Flagging or fencing
presents the defect in the certain gap happening between the metal layer and the
photoresist top surface with a extremely thinner metallization layer (Carpenter et al.,
2004). When the situation happened, the metal will dissolve along with the photoresist
and leaving a “flag” behind, a ragged pattern, which will cause uneven surface and the
failure of device fabrication (Golden et al., 2009; Roesch and Hamada, 2004).
In this chapter, we will describe the procedures for obtaining gold electrodes or
interconnects in detail. These electrodes can be used for electrokinetic manipulation,
local application of voltage or current, DNA immobilization, and so on. (benjamin Y.
part)
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3.2

Sensor fabrication

3.2.1 Materials and supplies
Ultraviolet (UV) flood exposure machine, evaporation machine, photoresist spinner, two
hot plates. Thermal Oxide coated (1 micron) silicon [Si] wafer, Lift-off Resist (LOR-5a),
Shipley 1827 positive photoresist, photoresist developer Microposit MF 319, Remover
PG, and Nano-Strip were used as receive in cleanroom.

3.2.2 Fabrication procedure
To fabricate the biosensor utilizing lift-off techniques, traditionally, the lift-off resist
(LOR) will be coated on the surface of the wafer firstly, and then the photoresist is spread
on. The chemical properties of LOR lead to no interacting or intermixing between these
two layers, LOR and photoresist. After exposed for patterning, the wafer coated with
both LOR and photoresist is immersed in develop solution. When the photoresist is
thoroughly developed, the developer will keep on dissolve off the LOR layer at the open
area. Thus, a small amount of standard photoresist developing time increase will
contribute to the LOR undercut properly for the following steps. The process of
developer dissolving LOR can be both isotropical and well-controled, which attributes
the high standard of precise undercut control of lift-off techniques (Golden et al., 2009).
The procedures and apparatus of fabricating electrodes can be summarized as Figure 3.1
and Figure 3.2, respectively.

Figure 3.1: Schematic of the electrode layer structures.
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Figure 3.2: Apparatus of main procedures for photolithography and metallization.

3.2.2.1

Substrate pretreatment

Before applying lift off resist (LOR) and photoresist, the substrate was clean and dried in
order to maximize process reliability. The wafer cleaning began with Nano-strip solvent
to wash off surface organic material, followed by de-ionized (DI) water rinse, and then
nitrogen blow dry. Afterwards, to completely dehydrate surface, the wafer was baking on
a hotplate at 200⁰C for 5 minutes. Due to outstanding adhesion of LOR to most
semiconductors (SiO2 in our case), HMDS (hexamethyldisilazane) primer is not
necessarily applied as adhesion promoter (MicroChem Corp, 2001).
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3.2.2.2

Lift-off resist coating

According to the data sheet of LOR resists,

LOR resists is a great candidate for

producing various film thicknesses with different spin-coat condition with minimum
defect generating. The dependence of the film thickness on spin speed is displayed in
Figure 3.3, which provides necessary information about the LOR spin-coating conditions.
For better lift-off results, the thickness of the LOR film should be thicker than the metal
deposition thickness; typically the thickness of the metal film is about 1.33 to 1.5 times.
The range of LOR spin speed is between 2,500 and 4,500 rpm without coating defect
generation but statistic uniformity. The spin-coating speed will adjust along with the area
of the substrates such as higher speeds suitable for smaller substrate and vice versa. The
coating parameter suited for LOR 5a best is listed in Table 3.1(MicroChem Corp, 2001).

Figure 3.3: Spin speed versus thickness for Lift-off resist series.
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Table 3.1: Recommended coating parameters for LOR 5A (MicroChem Corp, 2001)
Process Step

Process Parameters

Dispense volume

3ml (100-mm Si wafer)

Dispense mode

Dynamic 3-5 seconds

Dispense spin speed 200-500 rpm
Acceleration

10,000 (rpm) per second

Terminal spin speed 3,000 (rpm)

3.2.2.3

Spin time

45 seconds

Edge bead remover

EBR PG

Soft bake

The primary purpose of the soft is to remove the solvent and dehydrated the LOR film
and control the undercut rate during the development process. In this process,
temperature and bake time is critical. As shown in Figure 3.4 (a) and (b), the temperature
shows greater influences over the baking time. The parameters in our experiment are
bake at 160°C for 5mins.

Figure 3.4: The influence of soft bake time and temperature.
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3.2.2.4

Development process

In our case, we chose MF-319 for the developing solution. The experimental condition
was listed in Table 3.2. The whole process was performed on the automated machine set
the parameter as follow: rinsing for 30s, develop for 6 mins and rinsing and blow dry.
Table 3.2: Undercut size versus developing time.
Develop Time

1.5 – 2 mins 2 – 3 mins 3 – 4 mins

Undercut (2000 rpm and 200⁰C soft bake) 0 -2µm

3.2.2.5

2 -5µm

5 -7µm

O2 Descum

In order to get the best experimental results, before metal deposition, the wafer is optional
to clean by oxygen plasma etch, which is call oxygen plasma de-scum. The de-scum is a
short-time (2-3 minutes) etching by oxygen plasma to eliminate residue photoresist
leading to poor metal contact or adhesion.

3.2.2.6

Lift-off Process

The bottom layer is LOR, then it will require sufficient time to stripping of the LOR layer
and soaking in Remover PG overnight has the best results.

3.3

Biodetection

3.3.1 Immunoassay
As introduced in Chapter 1, immunoassay is the interaction between antibody and
antigen, which is the gold standard technique for cardiac biomarker detection and
determination, and is one of the most prevalent detection methods used in food safety,
environmental monitoring, biotechnological investigation, and clinical analysis (Lin et
al., 2010b; Mohammed and Desmulliez, 2011) .
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3.3.2 Working principle and classification
One of the immunoassay formats is that divided into heterogeneous and homogeneous
type. (Ha et al., 2009) When the antibody and antigen are immobilized on a solid
substrate forming the complex without further separation, the immunoassay is called
heterogeneous format. Because the immunoreaction happens on the surface of the
substrate, heterogeneous immunoassay has high surface area/volume ratio and excellent
analytical sensitivity. But immobilizing antibody or antigen on the solid substrate is
inextricable and sophisticated, for instance, hydrophilic protein molecules are difficult to
absorb on the hydrophobic polymer substrate without pretreatment. In contrast, when the
conjugation of antibody and antigen happens in the solution, the immunoassay is the
homogeneous

format.

Homogeneous

style

brings

the

multiplexing

and

fast

electrophoretic separations up to immunoassay, but being constrained by antibody or
antigen solution preconcentration (Lin et al., 2010a).
Traditional ELISA usually takes several hours and complicated process to get the final
results. As shown in Figure 3.10. However, the one-step electrochemical ELISA (Figure
3.11) can be simplifies the whole process into four steps without comprising the benefits
of the ELISA. Both detection systems are classic sandwich immunoassay principle,
which includes the following steps: monoclonal antibody coating on the surface and
antigen–detection antibody complex react with the capture antibody with a detectable
label.
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Figure 3.5: Working schematics of the traditional ELISA.

Figure 3.6: Schematics of the one-step electrochemical ELISA.

44

3.3.3 Procedures
3.3.3.1

Immobilization of cTnI capture antibody

One of the most critical steps is to immobilize the capture antibody on the surface of the
immunosensor. The response may present high background noise or poorly reactive of
the reaction of the probe, which will result in decreasing significantly the sensitivity or
the ratio of signal to noise of the immunosensor, due to the inappropriate binding of the
capture antibody (Corgier et al., 2005; Corgier et al., 2007; Lahann et al., 2003; Mao et
al., 2002).

3.3.3.2

Configuration of the immunosensor

As shown in Figure 3.12, the configuration of the immunosensor can be divvied into
base, which including the substrate, metal layer, and the mediator; immunoreaction, BSA,
capture antibody and detection antibody labeled with enzyme; and the signal generation,
which was catalyzed by the enzyme and generation free electron to obtain the
amperometric response.
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Figure 3.7: Configuration of cardiac troponin I immunosensor.

3.4

Conclusion

In this chapter, we have discussed about the fabrication process and configuration of the
immunosensor. The pattern from the mask was transferred to the substrate by lift-off
technique, in which lift-off resist and positive photoresist Shipley1827 was involved in
the photolithography process. Shipley1827 as the sacrificial layer was indirect contacted
with the substrate. Meanwhile, the fabrication process was being controlled by
temperature, developing time, exposing dose and other factor. The immunosensor was
constructed by classic sandwich ELISA: the complex of antigen and detection antibody
labeled with signal generating enzyme was captured by immobilized first antibody, and
BSA acting as a blocking membrane to eliminating non-specific binding interference.
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Chapter 4
4

Electrode modification and optimization

Electrochemical immunosensor brought tremendous interest for point-of-care diagnostics,
such as small sample volume, high sensitivity, and time efficiency. In this chapter,
nanomaterials modified immunosensor, carbon nanotube, and gold nanoparticles, were
designed, investigated, and optimized.

4.1

Introduction

As discussed before, troponin I (cTnI) plays a critical role in diagnosis and management,
prognosis of myocardial infarction. It is well known that electrochemical immunosensor
possesses tremendous promising properties such like specificity and detection simplicity,
cost efficiency, short assay time, and highly adaptable for miniaturization, has recently
drawn considerable attention. Various format immunosensors combined with
electrochemical techniques such as potentiometry, amperometry, or piezoelectry, have
been developed for electrochemical assays of the cTnI level (Ahammad et al., 2011;
Kurkina and Balasubramanian, 2012; Lin et al., 2011; Tang et al., 2011; Zhou et al.,
2010). For example, a multiplex cancer electrochemical immunosensor was recently
reported by Guo et al., which was a flow injection device as the screen-printed glassy
carbon electrode modified chitosan matrix to enhance molecular immobilization. The
cancer biomarker arrays were developed to determine several tumor markers
simultaneously without comprising experimental performance such as low detection limit
and high throughput (Guo et al., 2010).
Lately, the development of advanced materials and the utilization of nanomaterials in
biosensor gain more and more attentions from various research groups. Carbon nanotube
(CNT) possesses unique properties in terms of remarkable mechanical, electrical,
chemical and structural performance. CNT, the largest elastic materials among the world,
can play as metallic ions, semi-conductive materials with excellent electron
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transportation, and be suitable as a host for storing guest biomolecules as well (Davis et
al., 2003; Wang, 2005). Furthermore, CNT demonstrates substantial prospects in sensor
fabrication, both biosensor and immunosensor, in terms of excellent chemical stability,
extraordinary electronic properties, strong mechanical performance, and high surfacearea-to volume ratio(Lin et al., 2011). However, the CNT application was constrained by
the poor liquid dispersibility, particularly in DI water; therefore, introducing Poly
(diallydimethylammonium)

chloride,

a

water-soluble

quaternary

ammonium

polyelectrolyte, also called PDDA is used to improve the dispersibility of CNT. PDDA
was commonly used in water treatment, the mining industry operation, paper
manufacturing process and biological application (Rochette et al., 2005), and was found
to be capable of improving the homogeneity of CNT film by helping CNT disperse in the
water(Kim et al., 2003; Kim and Sigmund, 2003; Wen et al., 2007). There are two types
of CNT based on the production process: single-wall carbon nanotube (SWCNT) and
multi-wall carbon nanotube (SWCNT). We use MWCNT in all the following
experiments.
In electrochemical application, gold nanoparticles (AuNPs) can have various functions,
which can be classifies as: biomolecules immobilization, electron transfer enhancement,
catalyzing the reaction, function as biomolecules label and even act as a reactant (Luo et
al., 2006). Furthermore, AuNPs is also notable biocompatible materials, which can
create a native environment for bioconjugates or biomolecules. Therefore, AuNPs can be
the perfect candidate for the immobilization matrix because it can absorb biomolecules
firmly due to its large specific surface area along with high surface free energy without
destroying the biological activity of the antibody or antigens (Luckham and Brennan,
2010; Luo et al., 2006). However, the absorption capacity of AuNPs on the electrode
surface is not sufficient. Therefore, we introduce AuNPs doped with chitosan for electro
modification. On the one hand, chitosan is a natural biopolymer comprised of rich
hydroxyl function groups and active amino, which is one of the most popular candidates
for immobilization matrix (Cavalcanti et al., 2012).

On the other hand, the poor

conductivity leads chitosan to combining with other materials such like CNT, metal
nanoparticles, or redox mediators for biosensing in electrochemical platforms (Yang et
al., 2011).
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In this current work, we using PDDA-MWCNT and chitosan- AuNPs as the electrode
modification, for capture antibody immobilization and electron transfer enhancement to
construct a sensitive immunosensor for cTnI determination. In addition, based on such a
configuration, the experimental conditions were optimized and the linearity and
sensitivity were investigated.

4.2

Experimental

4.2.1 Chemicals
Troponin I from the human heart, the rabbit anti-human cTnI polyclonal antibody, and
the mouse anti-human cTnI monoclonal antibody were purchased from Sigma-Aldrich. 4Aminophenyl phosphate monosodium salt hydrate was obtained from Gold
Biotechnology (St. Louis, USA). Maleimide alkaline phosphatase and maleimide
horseradish peroxide were received from Innova Bioscience (Cambridge, UK). NSuccinimidyl S-acetylthioacetate (SATA), alkaline phosphatase stabilizing buffer,
sodium aside, diethanolamine (DEA), dimethylsufoxide (DMSO), bovine serum albumin
(BSA), p-nitrophenyl phosphate (p-NPP) liquid substrate, Trizma® base (tris(hydroxylmethyl)-aminomethane(Tris)), hydroquinone, potassium ferricyanide (III),
polyoxyethylenesorbitan manolaurate (TweenTM 20), and PDDA (20 wt % in water) were
all purchased from Sigma-Aldrich.
All these buffers. such like phosphate buffer solution (PBS), blocking buffer (1% BSA in
PBS) and etc., were prepared every week. The MWCNT (cylindrical with diameter range
in 5-15nm) with 95% purity was purchased from US Research Nanomaterials, Inc.
All the reagents and chemicals were analytical-reagent grade or better without any further
purification. Deionized (DI) water, with resistivity higher than 18 M (Milli-Q, USA),
was used throughout.
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4.2.2 Apparatus
Hitachi S-4500 field emission scanning electron microscope (SEM) along with the
energy dispersive X-ray spectroscope (EDX) was the equipment performed to
characterize the microstructure of the modified electrodes and all images were taken at 5
kV. The Varian UV-visible spectrophotometer were engaged to provide the control
experiment reference of cTnI in serum using a standard troponin I kit purchased from
GenWay Biotech, San Diego.
All electrochemical experiments were performed by a computer-interfaced CHI1200a
(CHI Instruments, Inc., USA). For traditional electrochemical cell, the bulk gold working
electrode (2 mm diameter), a platinum wire counter electrode, Ag/AgCl reference
electrode immersed in saturated KCl solution were incorporated into a classic threeelectrode electrochemical cell. All the electrodes and cell stand were all obtained from
CHI instruments, Inc., USA. For the planar electrode, as mention in chapter 3, three
electrodes along with leads and contact pads were fabricated on the silicon wafer with
100 nm silicon oxide layer. All the modifications only were applied on working electrode
(diameter 3mm). A dot of Ag/AgCl ink (AG-500, conductive compounds) was dropped
on the reference electrode, as shown in Figure 4.1.

Figure 4.1: Planar electrode and preliminary design for immunosensor embedded in
a microfluidic chip.
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4.2.2.1

Carbon nanotube preparation

In general, carbon nanotube needs to be immersed in strong acids, e.g. HNO3 or H2SO4,
to functionalize and purify. Hydrogen ion (H+) will cause carbon nanotubes rich in
carboxyl group (-COOH), which are vital for not only conjugate with biomolecules but
also absorb in the hydrophilic surface. Therefore, the MWCNT was firstly added into the
mixture of H2SO4 (98%) and HNO3 (60%) (3:1 (v/v)) for hydrophilic treatment for eight
hours (Kannan et al., 2009; Piao et al., 2009; Saito et al., 2002). Then the acid mixture
solution was removed from the supernatant and adds NaOH into MWCNT solution till
pH value reach 7 to neutralize the solution. Then to remove the residue NaNO3 and
Na2SO4 the following procedures were repeated several times: adding DI water to the
MWCNT solution, centrifugation the mixture and removing the supernatant. To form
MWCNT-PDDA composite, in 10 ml vial, adding 2 ml 8% PDDA and 2 mg MWCNT,
and the mixture was ultrasonicated for 1.5 h. The excess PDDA was removed by
centrifugation (higher speed) and washed with DI water till the mixture is stable. Then
the MWCNT-PDDA was ready for the following experiments. (Bi et al., 2009; Manesh et
al., 2008; Wang et al., 2011).

4.2.2.2

Preparation of chitosan-AuNPs

The gold nanoparticles were prepared using the protocols according to the literature
(Doron et al., 1995; Xue et al., 2006), by adding 2.5 mL of 1.0% trisodium citrate to the
100 mL of boiling HAuCl4, the concentration of which is 0.01 % (w/w). Keep the
mixture boiling and stirring for 10 minutes. Then pour the solution into a dark glass bottle
and use it in a week to prevent the AuNPs from agglomerating.
1% (wt%) chitosan solution was prepared, in a 15 mL vial, by adding chitosan powder
into 0.05 M acetic acid solution, and then ultrasonicated until the chitosan powder was
completely dissolved (Xue et al., 2006). Then mix the AuNPs solution with chitosan
solution together in volume ratio 1:1 to form the chitosan-AuNPs composite.
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4.2.3 Electrode preparation and pretreatment
For the bulk electrode, the Au electrode was polished with 0.1 and 0.1 m alumina slurry
on microcloth pads sequentially to physically remove the oxide layer, followed by rinsing
with double dilute water. Then the electrode was immersed in freshly prepared Piranha
solution (30% H2O2: H2SO4 = 1:3 (v/v)) to remove organic residue. Then the electrode
was ultrasonicated in DI water, acetone, and DI water for 5 minutes, respectively. To
further clean and activation, the electrode was immersed in 0.1 M sulfuric acid under a
cyclic voltage from 0.6 to 1.5 V with the scan rate of 50 mV s-1 till a stable
voltammogram established (Figure 4.1), then the electrode has been fully ready for
further electrochemical experiments (Elliott et al., 1999). For planar electrode, it will only
require the last step for cleaning and activating the working electrode.

Figure 4.2: Electrochemical cleaning and activation of electrodes in 0. 1 M sulfuric
acid by cycling between 0.6 V and 1.5 V at a sweep rate of 50 mV s-1.
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4.2.4 Electrode modification and characterization
To modify the electrodes, spread 5 L of the MWCNT-PDDA solution or chitosanAuNPs solution over the Au electrode surface, and then set it at the room temperature to
evaporate the solvent. After that, on the surface of the electrode, a film will form, which
can be visually observed.

4.2.5 Preparation of antibody-enzyme conjugates
The process was established through SATA as a crosslink to form a thiol function group
and then react with maleimide activated alkaline phosphatase (ALP). The schematic is
shown in Figure 4.2. The antibody-enzyme conjugation process is depicted as follows
(O'Regan et al., 2003; O'Regan et al., 2002).
(1) Prepare antibody stock solution. In 2 mL vial, adding 100 µL anti-cTnI polyclonal
antibody (1 mg/mL) and then adding 100 µL sodium phosphate buffer (50 mM
NaH2PO4 and 1mM EDTA, pH 7.5).
(2) Prepare SATA stock solution (1.5 mg/mL in DMSO).
(3) Add 5 µL SATA stock solution to antibody stock solution, and then gently shake the
vial and set at room temperature for 45 min.
(4) To remove the by-product (residue SATA) by centrifugation using a 30 kDa cut-off
ultracentrifuge filter (Sigma) against sodium phosphate buffer.
(5) Prepare deacetylation solution, 20 mL (50 mM NaH2PO4, 25 mM EDTA, 0.5 M
hydroxylamine– HCl, pH 7.5).
(6) Add to the antibody mixture and let it incubate for 2 hours at room temperature to
reveal the thoil group.
(7) Dialyse the solution against DPBS (137 mM NaCl, 2.6 mM KCl, 8 mM Na2HPO4, 1.5
mM NaH2PO4, 1 mM EDTA, pH 6.6) at room temperature for 12 h/ overnight.
(8) Add maleimide activated ALP to antibody solution based on molar ration 2:1
(1:1(w/w)) and then left in 4 ⁰C for 12 hours.
(9) Dialyze conjugates against Tris buffer (50 mM Trizma base, 50 mM NaCl, 1 mM
MgCl2, pH 7.4) for overnight at room temperature.
(10) Add ALP stabilizing buffer (Tris buffer, pH 8.0, 1% (w/v) BSA and 0.05% (w/v)
sodium azide) to adjusted to a final volume of 500 mL. Then store the conjugates at 4 ⁰C.
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Figure 4.2: Illustration of antibody-ALP conjugates: (a) Attachment to antibody, (b)
deprotection, and (c) reaction with ALP, (d) Conjugates. Adapted from (Life
Technologies)

4.2.6 Immunoassay protocols
The immunoassay utilized in the current work is 2-site enzyme-linked-immunosorbent
serologic assay (ELISA), also called as sandwich type ELISA. Therefore, the
immunoassay protocols include three principal procedures:

incubate first antibody,

blocking, and incubation antigen-antibody-ALP. First, incubate the capture antibody.
Add 5 µL capture antibody solution (anti-cTnI monoclonal in carbonate buffer, pH 9.5)
and incubate for 60 minutes at 37 ⁰C, and then rinsing thoroughly with washing buffer
(0.05% Tween® in PBS, pH 7.4) to remove the unbound antibodies. Then add a drop of 5
µL 10% (w/v) BSA in PBS (pH 7.4) and incubate for 60 minutes at 37 ⁰C, to block the
non-specific bounding. Afterwards, repeat washing by 0.05% Tween® in PBS. Finally,
incubate the premixed antigen-antibody-ALP a drop of 5 µL, incubate for 60 minutes at
37 ⁰C. Then the electrode would be ready to move on the electrochemical experiments.
For the bulk electrodes, after each immunoassay run, immerse the electrode into 0.1 M
glycine-HCl (pH 2.0) for 5 min and rinse by double dilute water. Then start from
electrode pre-treatment to carry out another sensing cycle (Gao et al., 2003).
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4.2.7 Electrochemical detection
Electrochemical measurements were done in a conventional electrochemical cell or on a
flat chip, which is the macroscale prototype of at the room temperature. Firstly, Cyclic
voltammograms (CVs) were performed 2 mM PBS (pH 6.5) containing 5.0 mM
K3[Fe(CN)6]/K4[Fe(CN)6] (1:1) mixture and 0.1 M KCl from 0.6 to −0.2 V (vs. Ag/
AgCl) at the scan rate of 50 mV s−1 to monitor the current variation (∆I) before or after
nanomaterial modification because PDDA-MWCNT and chitosan-AuNPs will increase
the electron transferring and lead to current response enlarged (Gao et al., 2003).
Secondly, the immunoreaction was monitored by cyclic voltammograms performed in
PNPP (p-nitrophenyl phosphate) liquid substrate (pH 9.0) purchased from Sigma. When
the antigen has bound with both antibodies: capture antibody helping coated on the
surface of the electrode and the second antibody (labelled with ALP) catalyzing the
substrate to generating current response, then there is current response of the
immunoreactions. All the electrochemical experiments were carried at the room
temperature.

4.3

Results and discussion

4.3.1 Electrochemical characteristics of bare electrode
After polished, ultrasound, and strong acid clean, to clarify that the electrode is ready for
experiment: Cyclic voltammograms (CVs) were performed in 0.02 M PBS (pH 6.5)
containing 5.0 mM K3[Fe(CN)6]/K4[Fe(CN)6] (1:1) mixture and 0.1 M KCl from 0.6 to
−0.2 V. The ideal difference between redox peak should be 67 mV (Tang et al., 1988),
which is barely happening in the realistic. As long as the difference ranges between
60 mV to 100 mV, then the electrode can perform well. If the potential difference of the
peak of redox current is over 100 mV, then the electrode needs further clean which may
start from the electrode pre-treatment. Here, Figure 4.2 shows the cleaned electrode with
71 mV difference, indicating the electrode been cleaned, activated and ready for the
following experiments.
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Figure 4.3: Electrochemical indication in 0.02 M PBS (pH 6.5) containing 5.0 mM
K3[Fe(CN)6]/K4[Fe(CN)6] (1:1) mixture and 0.1 M KCl from 0.6 to −0.2 V.

4.3.2 Characteristics of CNT, AuNP
Adding PDDA into MWCNT solution leads to phenomenal improvement of the
dispersibility of MWCNT in water. In addition, the stability has been remarkably
enhanced, for example the homogeneous, well-soluble suspension of PDDA-MWCNT
could be stored stably for months.

The characterization of the PDDA-MWCNT

composite, morphology and structure were shown in Figure 4.4. Figure 4.4 (a) shows the
homogeneous and porous film comprised of PDDA-MWCNT (Suprun et al., 2011),
which is evenly spread on the surface of the working electrode. On the contrary, Figure
4.4 (b), the inset of Figure 4.4 (a), demonstrated conglobation comprised by MWCNT
without treatment, ending up with a uniform surface, indicating the enormous value of
PDDA in dispersing MWCNT (Wen et al., 2007). Figure 4.4 (c) displays the
characterization of gold nanoparticles (AuNPs), which would significantly increase the
coverage of capture antibody anti-cTnI
nanospheres structure (Suprun et al., 2010).

due to large surface-to-volume ration of the
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Figure 4.4: SEM images of (a) PDDA-MWCNT composite; (b) MWCNT without
any treatment; (c) AuNP composite on the surfaces of gold electrodes.

4.3.3 Cyclic voltammetry characterization of PDDA-MWCNT modified
electrodes
The cyclic voltammetry in various scan rates was shown in Figure 4.5. It can be observed
that both the peak currents of anode and cathode were increased with the scan rate. In
addition, the difference between peak currents of anode and cathode was enlarged as
well. Both the anodic and cathodic currents were proportional to the square roots of scan
rate, from 10 mV s-1 to 500 mV s-1 , indicating that the redox process is diffusion
controllable.
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Figure 4.5 (a) The cyclic voltammograms of PDDA-MWCNT-Au electrode at
various scan rates from 10 to 500 mV s-1 in 0.02 M PBS (pH 6.5) containing 5.0 mM
K3[Fe(CN)6]/K4[Fe(CN)6] (1:1) mixture and 0.1 M KCl from 0.6 to −0.2 V. (b) The
dependence the redox peak current over the square root of the various scan rates.
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4.3.4 Cyclic voltammetry characterization of PDDA-MWCNT and
AuNPs modified electrodes
Utilizing cyclic voltammetry (CV) to characterize the modified PDDA-MWCNT and
chitosan-AuNPs electrodes are based on the redox reaction of ferricyanide, as shown in
equation (4.1). Herein, we choose 5 mM K3Fe(CN)6 along with 0.1M KCl solution to
probe the reduction or oxidation on the surface of the electrodes. Figure 4.6 shows
various modifications of the electrodes in the probing solution.

Fe(CN)64- ↔ Fe(CN)63-+ e-

(4.1)

In figure 4.6, curve a stands for the PDDA-NWCNT, which we can observe a smooth
curve with a couple of well-formed redox peaks and compare with the rest three curves,
the redox peaks are the largest, indication that the PDDA- MWCNT has the strongest
ability of enhancing electron transfer among the other three. Curve c shows the bare
electrode response of ferricyanide redox reation. Curve d displays the electrode after
modified by chitosan without AuNPs, both the peaks shrunk dramatically suggesting that
the chitosan molecules act as a blocking layer for the electron and mass transfer and stop
the diffusion of ferricyanide (Wen et al., 2007). The blocking effect of the film can be
caused by the poor conductivity of pure chitosan, the result of which agrees with the
insulation of curve b.

As curve b shows, the current response (curve b) increases

significantly when the AuNPs were entrapped with chitosan. That is might be the AuNPs
increase the conductivity of the film by facilitating the electron transferring. However,
the result of electron transfer enhancement is not as good as PDDA-MWCNT, which may
cause by the poor conductivity of pure chitosan as well.
Accordingly, the cyclic voltammetry (CV) characterization confirms the theory that
modifying the electrode surface by PDDA-MWCNT and chitosan-AuNPs could
facilitating the electro transfer for better electrochemical performance.
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Figure 4.6: CVs of different modified electrodes in a 5 mM K3Fe(CN)6 solution
containing 0.1M KCl (pH 6.5): (a) PDDA- MWCNT; (b) Chitosan- AuNP; (c) Bare
electrode; (d) Chitosan.

4.3.5 CV characterization of cTnI immunosensor
To investigate the PDDA-MWCNT and chitosan-AuNPs electrochemical behaviour in
the immunosensors, modified electrode along with bare electrode followed the
immunoassay protocol to incubate with cTnI antigen (50 ng/mL) and alkaline
phosphatase (ALP) labelled second antibody. Then all the sensors were characterized by
CV scan in PNPP liquid substrate (5mM, pH 9.0). Since the existence of antibody label
ALP in the solution, it will catalyze the PNPP hydrolyzing into PNP, which leads to tense
electron transferring to form a well-defined oxidation peak. The scan potential range is
from -0.8 to 1.2 V, and the current peak appears at about 1.0V. The amperometric
response should be proportional to the amount of ALP, which were labelled with the
second antibody.

Since sandwich ELISA is highly sensitive and specific reaction,

theoretically, the current response would be proportionally related to the antigen
concentration, saying, cTnI. Figure 4.9(a), 4.10 (a) and 4.11(a) display the various current
response of different concentration of the cardiac troponin I.
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As shown in figure 4.7, various modifications have distinct peak value of the oxidation.
Curve (a) stands for blank curve: No cTnI involved in the immunoreaction, therefore, no
current response or peak value. Curve (b) indicates the bare electrode current varies on
potential shifts. Curve (c) and (d) demonstrate the bare electrode current varies on
potential shifts on chitosan-AuNPs and PDDA-MWCNT. As shown in figures, the peak
current value of PDDA-MWCNT is twice larger than chitosan-AuNPs, and three times
bigger than bare electrode, which can be explained by the following causes: First, the
roughness on the electrode surface is from high to low: PDDA-MWCNT, chitosanAuNPs, bare electrode. The rougher surface and the easier to immobilize the capture
antibody, which is a key step for signal generation. Second, as discussed before, the poor
conductivity of pure chitosan hinders the electron transfer to a certain extent, especially
compared to the great electron transfer prompter, PDDA-MWCNT.

Figure 4.7: Electrochemical behavior of various modified electrodes in
immunoassay: (a) blank, (b) bare electrode, (c) chitosan-AuNPs electrode, (d)
PDDA-MWCNT modified surface.
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4.3.6 Optimization of immunoassay procedure
There have been many factors capable of obstructing the performance of the
immunosensor such like the pH value of the liquid substrate, the amount of immobilized
cTnI antibody, the temperature and the incubation time etc.. Herein, the experimental
condition optimization was implemented on unmodified electrodes. The amount of the
capture antibody on the immunosensor to grab antigen-antibody-ALP is critical and
influential for the overall performance of either PDDA-MWCNT or chitosan-AuNPs
immunosensor. Then, all the experiments of optimizing experimental conditions were
carried on bare electrode except other specifically addressed. The influence caused by
different substrates will be addressed in the next chapter. Herein, the substrate, PNPP
liquid substrate, was used as directly purchased from sigma. The concentration of the
analyte, cTnI, is 30 ng ml−1. Figure 4.8 (a) illustrates that the relationship between the pH
value and the sensitivity. The results the sensitivity increases along with the elevated pH
value from 6.1 to 10.0, and then followed by a significant drop. Therefore, take both
stability and bioactivity into consideration, the pH value 9.0 was used in the following
experiments. Figure 4.8 (b) presents the capture antibody concentration influence of the
experiment results. As shown in the figure, the currents response increases sharply before
the immobilized antibody concentration reached 20 µg ml−1 and then the rate of increased
has been slowing down. After 40 µg ml−1 the response tends to be decreased, which
might be caused the blocking effect of excess antibody. Therefore, the antibody
concentration was as 20 µg ml−1 due the cost and the sensitivity. Figure 4.8 (c)
demonstrates that the temperature effect on the immunosensor performance. Herein, we
only take four different temperatures tested in the identical experiments: 4⁰C, 20⁰C,
37⁰C, and 50⁰C, due to the limit of the experiment conditions. The experiment response
reached the peak when the temperature was 37⁰C, which is consisted with most literature,
it might be caused by the protein reaction, antigen and antibody, reached the high
bioactivity leads to the better conjugates. Figure 4.8 (d) incubation time stands for
different incubation time for two different concentrations of cTnI, 10ng ml−1 and 50ng
ml−1. When the incubating time reached 20 minutes, the reaction was almost 70%
finished and reached the stable till 45 min. Therefore, the incubation time was set as 20
mins.

62

63

Figure 4.8: Influence of (a) pH value; (b) capture antibody concentration;
(c) temperature; (d) incubation time on the immunosensor.
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4.3.7 Calibration curve of the cTnI immunosensor
After the optimization experiments, the calibration curves were established under the
optimized conditions to determine cTnI using PDDA-MWCNT and chitosan-AuNPs
modified electrodes. The oxidation peak currents occur between 0.9 to 1.0 V, as shown
in Figure 4.9 (a), 4.10 (a) , and 4.11 (a). The reaction between antibody and antigen was
based on sandwich ELISA mechanism. The antigen first react with detection antibody
conjugated with ALP label, and then react with immobilized capture antibody. The ALP
label increase will lead to current response elevated which is owing to the increasing
amount of antigen, cTnI. As shown in Figure 4.9 (a), 4.10 (a) , and 4.11 (a), the peak
current increases along with the concentration increasing. Then the dependence of the
CV oxidation peak current on the cTnI concentration is linear ranging from 1.0 ng ml −1 to
100ng ml−1 on bare gold electrode, 0.01 to 300 ng /ml on PDDA-MWCNT electrode, and
0.02 to 200 ng ml−1 on chitosan-AuNPs electrode, with a correlation coefficient of 0.978,
0.983, and 0.971 respectively.
In terms of detection linear range and the correlation coefficient, the PDDA-MWCNT
electrodes have the widest range comparing to chitosan-AuNPs electrodes and bare
electrodes. It can be caused by the unique properties of carbon nanotube such as chemical
stability, high surface-volume ratio, capacity of electron transferring and etc.
Furthermore, speaking to the AuNPs modified electrodes, comparing to bare electrodes,
with relatively low r2 (correlation coefficient), it might be explained by the
biocompatibility of chitosan and AuNPs, which can help absorb more capture antibody
and more non-specific binding, which further indication the non-selective properties
between chitosan and AuNPs to biomolecules. The sensitivity of three electrodes will be
discussed in the following session.
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Figure 4.9: (a) The current-voltage response curves (b) calibration curve of bare
gold electrodes.
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Figure 4.10: (a) The current-voltage response curves (b) calibration curve of
chitosan-AuNPs modified gold electrodes.
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Figure 4.11: (a) The current-voltage response curves (b) calibration curve of PDDAMWCNT modified gold electrodes.
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Figure 4.12: Calibration curve of PDDA-MWCNT, AuNPs, and bare electrode.

The detection limits were obtained by triplicate measurements of blank detection and
then was calculated to be 0.1 ng ml−1on bare gold, 0.001 ng ml−1 on PDDA-MWCNT,
and 0.003 on chitosan-AuNP respectively, which was compared with current POCT
device detection limit as shown in the Table 4.1. The sensitivity stands for the slope of
the calibration curve, (Katus et al., 1989), in our case, the sensitivity is 18.32 µA mg-1mL1

on bare gold, 32.17 µA mg-1mL-1 on PDDA-MWCNT, and 40.15 µA mg-1mL-1 on

chitosan-AuNP respectively (Figure 4.12). When the concentration of cTnI reached over
the range higher limits, then it will need to be diluted prior to the experiments. It consists
with the relative literature indicated that the application of AuNP and CNT can enhance
the catalytic reaction and enhance the sensitivity (Burlina et al., 1994). The enhanced
sensitivity is perhaps due to the synergistic effect of AuNP or CNT.
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Table 4.1: Characteristics of current cTnI POC assays. Adapted from (Christenson
and Azzazy, 2009)
Assay

Lower detection
limit(ng ml−1)

99th percentile cutoff
value (ng ml−1)

Receiver- operating
characteristic curve cutoff

Abbott i-STAT

0.02

0.08

—

Dade CS

0.03

0.07

0.6-1.5

Response

0.03

< 0.05

—

Biosite Triage

0.19

<0.19

0.4

4.3.8 Stability and reproducibility of the cTnI immunosensor
We investigated the storage stability of the current project. The electrodes were stored in
the refrigerator at 4 °C and then examined every day for the activity. The electrodes
include PDDA-MWCNT, AuNPs, and bare electrodes. The results as shown in Figure
4.12, for all the three electrodes, there were no significant signal decrease being observed
before first 20 days. However, the bare electrodes started to decrease immediately after
20 days. The activities of PDDA-MWCNT and AuNPs remained the same response with
a few fluctuations between day 20 till day 27, then both of responses of the PDDAMWCNT and AuNPs drop sharply.

Besides the stability of storage, the stability of operation, the interassay variation
coefficient is critical as well. We investigated the interassay variation coefficient by
measuring the same sample by five sets of PDDA-MWCNT and AuNPs electrodes,
respectively. The results illustrated that the interassay variation coefficient was
20 ng ml−1 was 5.8% of PDDA-MWCNT and 20 ng ml−1 was 6.4 % AuNPs, which
indicating both PDDA-MWCNT and AuNPs has considerable potential for fabrication
stability and enduring storage stability.
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Figure 4.13: Storage stability of the PDDA-MWCNT, AuNPs and bare electrodes.

4.3.9 Accuracy and clinical application
Herein, we study the accuracy of the cTnI immunosensor by comparing the results by
determining cTnI in human serum (diluted by PBS buffer pH 7.4 (v: v=1:10)) with
PDDA-MWCNT electrochemical immunoassay (EIA) and with spectrophotometric
ELISA. As presented in Figure 4.14, the mean values of evaluations in 5 serum samples
were performed at five different concentrations, and the error bar stands for the degree of
the measurement uncertainty. In addition, as shown in Table 4.2, the relative standard
deviation (%), square root of the variances, of PDDA-MWCNT is in the range of 2.94 to
8.56%, and the difference between Chitosan-AuNPs is from 3.92 to 6.86% in extent.
Both the figure and the data demonstrated that the measured value of cTnI concentration
by spectrophotometric methods shows satisfying agreements with both modified
immunosensor based electrochemical methods.

71

Figure 4.14: Measurement of cTnI with spectrophotometric, the electrochemical
with chitosan-AuNPs, PDDA-MWCNT methods in various concentration: 0, 1, 10,
20, 50 ng ml-1.

Table 4.2: Comparison of Measured cTnI levels between two methods.
Samples
(ng ml1

)

Spectrophotometric
-1

(ng ml )

PDDA-MWCNT
Electrochemical
(ng ml-1)

ChitosanRSD

AuNPs

RSD

(%)

Electrochemical

(%)

-1

(ng ml )

0

0.01±0.02

0.06±0.03

-

0.04±0.02

-

1

1.02±0.15

0.99±0.15

2.94

1.09±0.16

6.86

10

10.04±0.70

10.9±5.50

8.56

10.7±2.51

6.57

20

20.40±1.02

19.2±7.96

5.88

19.6±5.01

3.92

50

50.7±2.54

47.7±4.89

5.92

48.1±5.51

5.13
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4.4

Conclusions

We designed and developed an amperometric cardiac Troponin I immunosensor based on
PDDA-MWCNT and AuNPs, respectively. The electrochemical immunosensor was
based on sandwich type ELISA, which employs two antibodies and leads to high
sensitivity. The substrate utilizing in the experiment is commercially available and have
relatively high stability. The immunosensor presents good sensitivity, positive
bioactivity, low detection limit and quick response time and tolerable stability. The
immunosensor not only can be utilized on serum to determine cTnI values but also can be
applied of different protein molecules.
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Chapter 5
5

HRP- and ALP-label enzyme comparison study

This chapter will study characteristic of two enzyme label and various liquid substrate for
electrochemical signal response. TMB and HQ for horseradish peroxide enzyme was
studies in pH value 5.0 and 7.4, respectively; PNPP and PAPP in Tris buffer and DEA
buffer was investigated in alkaline system. HRP-based electrochemical biosensor along
with glucose biosensor can be integrated together to accomplish a cardiac-blood
chemistry sensor in POCT device. Also, a concept of multiplex cardiac biomarker
detection was presented.

5.1

Introduction

As discussed before, the immunoassay herein is to detect the antigen (cTnI) between two
antibodies. One of the antibodies was labeled with certain enzyme, which can catalyze
redox reaction of the corresponding substrates. Among all the enzyme-based
electrochemical biosensor, there are two most commonly used as the enzyme label for
signal amplification and catalytic reactions: horseradish peroxidase (HRP) and alkaline
phosphatase (ALP). In general, as in HRP-based biosensors (Crew et al., 2007; FanjulBolado et al., 2005; Ionescu et al., 2005; Ionescu et al., 2004; Sun et al., 2001; Volpe et
al., 1998), the signal responses generate by substrates electroreduced by the existence
HRP. In contrast, in ALP-based biosensors (Aziz et al., 2007; Aziz et al., 2008; Das et
al., 2007; Fanjul-Bolado et al., 2007; Hwang et al., 2005; Kwon et al., 2008;
Preechaworapun et al., 2008; Wilson and Rauh, 2004), the electrochemical responses
were induced by the electrooxidation of the ALP.
Since both HRP-based biosensor and ALP-based biosensors have quite long history as
the catalyzing label in ELISA immunoreaction, the overall performance of HRP-based
sensors have distinguishable disadvantages from the ALP-based sensors during the
electrochemical detections.

Comparing to the ALP-based sensors, most HRP-based
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sensors have higher background-current levels and less reproducible, which contributes
to more difficulty in achieving low detection limits. One the one hand, the majority of the
liquid substrates of HRP (such like hydroquinone (HQ)) is unstable and highly
electroactive under an narrow electrochemical potential window (Crew et al., 2007;
Fanjul-Bolado et al., 2005; Ionescu et al., 2005; Ionescu et al., 2004; Sun et al., 2001;
Volpe et al., 1998), while the substrate for ALP is less electroactive (Gyurcsanyi et al.,
2002; Preechaworapun et al., 2008), for instance, the PNPP liquid substrates discussed in
Chapter 4.

Therefore, the interference caused by electroactive substrates will

dramatically elevated the background-current level of the HRP-based sensors. On the
other hand, the hydrogen peroxide (H2O2) is the critical and necessary oxidizing element
in HRP catalysis sensor, which is prone to be electroreduced under a certain level of
electrochemical potential window. Consequently, the presence of H2O2 electroreduction
will potentially enhancing the background-current levels.
However, the relatively poor performance of HRP can be overcome by electrochemical
strategy in terms of lowing the background-current (Kang et al., 2009). In addition, the
unique merit of HRP-based biosensor instead of ALP-based biosensor is the great
potential to combine with Glucose or other blood chemistry biosensor (applicable to all
the analytes share with the same detection principle with glucose), using hydrogen
peroxide (H2O2) as the bridge. Over the past several decades, the enzymatic
amperometric glucose biosensor has drawn significant from the merchants and scholars
owing to the significant sensitivity, robust, and cost-efficient (Heller and Feldman,
2008). Regardless of the various formats or detection methodology, the fundamental
format of the glucose biosensor is that the glucose biosensor is using the enzyme glucose
oxidise (GOx) immobilization to catalyze the reaction between oxygen and of β-Dglucose, which will generate hydrogen peroxide (H2O2) and by-product gluconolactone
(Weibel and Bright, 1971). Therefore, in theory, the hydrogen peroxide (H2O2) generated
by glucose biosensor can be utilized as the oxidizing element in HRP catalysis sensor.
Then the investigation and discussion about the cTnI-glucose biosensor is depicted as
follows.
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5.2

Experimental

5.2.1 Materials and reagents
All the reagents and chemicals are or high than analytical grade without further
purification. All the buffers and solution were prepared with deionized water (DI), with
resistivity over 18MΏ.
Troponin I from human heart, the rabbit anti-human cTnI polyclonal antibody, and the
mouse anti-human cTnI monoclonal antibody were purchased from Sigma-Aldrich. 4Aminophenyl phosphate monosodium salt hydrate was obtained from Gold
Biotechnology (St. Louis, USA). Maleimide alkaline phosphatase and maleimide
horseradish peroxide were received from Innova Bioscience (Cambridge, UK). NSuccinimidyl S-acetylthioacetate (SATA), horseradish enzyme stabilizing buffer, sodium
aside, diethanolamine (DEA), dimethylsufoxide (DMSO), bovine serum albumin (BSA),
p-nitrophenyl phosphate(p-NPP) liquid substrate, Trizma® base (tris-(hydroxylmethyl)aminomethane(Tris)), TMB liquid substrate, hydroquinone, potassium ferricyanide (III),
polyoxyethylenesorbitan manolaurate (TweenTM 20), β-D-glucose, glutaraldehyde and
PDDA (20 wt % in water) were all purchased from Sigma-Aldrich.
All these buffers. such like phosphate buffer solution (PBS), blocking buffer (1% BSA in
PBS) and etc., were prepared every week. The MWCNT (cylindrical with diameter range
in 5-15nm) with 95% purity was purchased from US Research Nanomaterials, Inc.

5.2.2 Preparation of antibody-enzyme conjugates
HRP conjugating with antibody is extremely familiar with the ALP procedures. The
process was established through SATA as a crosslink to form a thiol function group and
then react with maleimide activated horseradish peroxide (HRP). The antibody-enzyme
conjugation process is depicted as follows (Fragoso et al., 2011; O'Regan et al., 2003)
(1) Prepare antibody stock solution. In 2 mL vial, adding 100 µL anti-cTnI polyclonal
antibody (1 mg/mL) and then adding 100 µL sodium phosphate buffer (50mM
NaH2PO4 and 1mM EDTA, pH 7.5).
(2) Prepare SATA stock solution (1.5 mg/mL in DMSO).
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(3) Add 5 µL SATA stock solution to antibody stock solution. Then gently shake the vial
and set at room temperature for 45 min.
(4) To remove the by-product (residue SATA) by centrifugation using a 30 kDa cut-off
ultracentrifuge filter (Sigma) against sodium phosphate buffer.
(5) Prepare deacetylation solution, 20 mL (50 mM NaH2PO4, 25 mM EDTA, 0.5M
hydroxylamine– HCl, pH 7.5).
(6) Add to the antibody mixture and let it incubate for 2 hours at room temperature to
reveal the thoil group.
(7) Dialyse the solution against DPBS (137 mM NaCl, 2.6 mM KCl, 8mM Na2HPO4, 1.5
mM NaH2PO4, 1 mM EDTA, pH 6.6) at room temperature for 12 h/ overnight.
(8) Add maleimide activated HRP to antibody solution based on molar ration 2:1
(1:1(w/w)) and then left in 4 ⁰C for 12 hours.
(9) Dialyze conjugates against Tris buffer (50 mM Trizma base, 50 mM NaCl, 1 mM
MgCl2, pH 7.4) for overnight at room temperature.
(10) Add HRP stabilizing buffer (Tris buffer, pH 8.0, 1% (w/v) BSA and 0.05% (w/v)
sodium azide) to adjusted to a final volume of 500 mL. Then store the conjugates at 4 ⁰C.

5.2.3 Construction of PB-PDDA-MWCNT Glucose Biosensor
To construct the PB-PDDA-MWCNT glucose biosensor includes the following steps:
(1) Electrodes pretreatment and activated and construct PDDA-MWCNT sensor: follow
the same procedures in Chapter 4, as shown in Figure 5.1 (a).
(2) PB film deposition: to electropolymerize PB by immersing the electrodes in a
solution comprised of 5 mM K3[Fe(CN)6], 5 mM FeCl3, 0.01 M HCl and 0.1 M KCl,
and scan from -0.1 to 0.4 V at 20 mV/s for 20 cycles (Figure 5.2 (b)) (Karyakin,
2001; Karyakin et al., 1995; Karyakin et al., 1996, 2000; Karyakin et al., 2004), and
then washed with double diluted water.
(3) PB activation: immerse the electrode into a solution with 0.1 M KCl and 0.01 M HCl
as the support electrolyte solution and activated by scan from -0.1 to 0.4 V at 50 mV/s
till the CV curve stable (Figure 5.1 (c)) (de Mattos et al., 2003; MATTOS et al., 2000;
Ricci et al., 2003). Then the electrode was cleaned by deionized and heated at 110 C
for 1 h.
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(4) Glucose biosensor: this step is to immobilize enzyme GOx on the electrodes, which
can be immobilized in two different ways. In order to be a control experiment for
cTnI-glucose sensor, the electrodes was with the presence of capture antibody.
Namely, combine L GOx (10 mg/mL) with 10 L chitosan (0.5%) to obtain the
GOx-chitosan mixture and then drop 5 L mixture on the surface of PB-PDDAMWCNT electrode, wait till the mixture evaporate at room temperature. As shown in
Figure 5.1 (d), the CV difference between with or without glucose presence.
(5) Immobilization of GOx: besides immobilizing with chitosan, also the GOx can be
mix with BSA solution (1%, w/V) first, and dropped the mixture on the surface of
working electrode and then immerse into 0.25% glutaraldehyde for 10 minutes to
generate a cross-link.

Figure 5.1: Cyclic voltammograms of the electrode pretreatment and PB-glucose
sensor construction. (a)Electrode cleaned and activated in 0.5M sulfuric acid; (b) Pb
electropolymerization; (c) Pb activation; (d) Biosensor in the null and 5mM glucose.
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5.2.4 Electrochemical and immunosensing experiments
The immunoassay utilised in the current work is 2-site enzyme-linked-immunosorbent
serologic assay (ELISA), also called as sandwich type ELISA. Therefore, the
immunoassay protocol includes three major procedures:

incubate first antibody,

blocking, and incubation antigen-antibody-HRP. First, incubate the capture antibody.
Add 5 µL capture antibody solution (anti-cTnI monoclonal in PBS solution, pH 6.0) and
incubate for 60 minutes at 37 ⁰C. Then rinsing thoroughly with washing buffer (0.05%
Tween® in PBS, pH 6.4) to remove the unbound antibodies, and add a drop of 5 µL 10%
(w/v) BSA-GOx in PBS (pH 6.0) and incubate for 60 minutes at 37 ⁰C, to block the nonspecific bounding. Afterwards, repeat washing by 0.05% Tween® in PBS. Finally,
incubate the premixed antigen-antibody-HRP a drop of 5 µL, incubate for 60 minutes at
37 ⁰C. Then the electrode would be ready to move on the electrochemical experiments.
For the bulk electrodes, after each immunoassay run, immerse the electrode into 0.1 M
glycine-HCl (pH 2.0) for 5 min and rinse by double dilute water. Then start from
electrode pre-treatment to carry out another sensing cycle (Gao et al., 2003).
All electrochemical experiments were performed by a computer- interfaced CHI1200a
(CHI Instruments, Inc., USA). Electrochemical measurements were done in a
conventional electrochemical cell or on a flat chip, which is the macroscale prototype of
at the room temperature. Firstly, Cyclic voltammograms (CVs) were performed 2 mM
PBS (pH 6.5) containing 5.0 mM K3[Fe(CN)6]/K4[Fe(CN)6] (1:1) mixture and 0.1 M KCl
from 0.6 to −0.2 V (vs. Ag/ AgCl) at the scan rate of 50 mV s−1 to monitor the current
variation (∆I) before or after nanomaterial modification because PDDA-MWCNT and
chitosan-AuNPs will increase the electron transferring and lead to current response
enlarged (Gao et al., 2003). Secondly, the immunoreaction was monitored by cyclic
voltammograms performed in TMB liquid substrate (pH 5.0) or HQ in PBS (pH 7.4)
along with a small concentration of H2O2 purchased from Sigma. When the antigen was
bound with both antibodies: capture antibody coated on the surface of the electrode and
the second antibody (labelled with HRP) catalyzing the substrate to generating current
response, then there was current response of the immunoreactions. All the
electrochemical experiment was carried at the room temperature.
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5.3

Results and discussion

5.3.1 Principle of the glucose- cTnI immunosensor
As shown in Figure 5.2, schematics indicate the concept of the glucose-cTnI
immunosensor with the surface modified electrodes. In the scenario of without antigen,
the sensor was modified by PDDA-MWCNT, Prussian blue, monoclonal anti-cTnI
antibody and BSA-GOx with glutaraldehyde as the cross-link, from the bottom (the bare
electrode surface) to the top. When the solution without cTnI was added in the reaction
chambers, the glucose oxidize will catalyze the reaction of glucose and oxygen,
generation hydrogen peroxide (H2O2) and gluconolactone. The product H2O2 will be
detectable by Prussian blue, which is the quantization of the amount of glucose. While, in
the scenario of with antigen cTnI,

the glucose oxide (GOx) will first catalyze the

reaction of glucose and oxygen to generate hydrogen peroxide (H2O2). Subsequently, the
hydrogen peroxide will participate in the immunoassay reaction, acting as the oxidizing
reagent to electrooxidized the horseradish peroxide (HRP) substrate under the
canalization of HRP. Then the results will be used to calculate the amount of cTnI.
The reaction happened in chambers without antigen is shown as follows:
GOD
Glucose  O2 
 Gluconolactone  H2 O2

Besides the glucose reaction with oxygen, the following reaction can be happening
depending on the adding substrates:

or
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Figure 5.2: Schematics and principle of the cTnI- glucose biosensor. Reprinted with
permission from (Henares et al., 2010)

5.3.2 Glucose deterimination
5.3.2.1

Electrochemical behavior of PB-PDDA-MWCNT electrode

Cyclic voltammograms of PB-PDDA-MWCNT electrode in PBS (pH 6.78) illustrates
that the existent of PB introduced a standard redox peaks at the potential 0.27 and 0.2 V
respectively, which was generated by the redox reaction from PB to Prussian white (PW)
(Zeng et al., 2008). Figure 5.3 (a) displays the CV response of PB electrode under
increasing scan rate. When the value of scan rate increases, the anodic, cathodic peak
currents, and the difference value between peak currents rise. Figure 5.3 (b) presents that
the redox peak current is linear to the square root of the scan rate from from 30 mV/s to
300 mV/s. It demonstrates that the redox reaction of PB on PDDA-MWCNT electrodes is
a diffusion controllable redox process.
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Figure 5.3: (a)Cyclic voltammograms of PB-PDDA-MWCNT electrodes at various
scan rates from 30 to 300 Mv S in PBS (pH 6.78). (b) The dependence of the current
of redox peaks over the square root of the scan rate.
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5.3.2.2

GOx immobilization

Immobilization of glucose oxidize is a critical step in the experiments. Two different
methods were used in this case to investigate the influence of GOx immobilization in
terms of sensitivity and the dynamic range of the linearity. First, the GOx was mixed with
chitosan immobilization matrix and dropped on the electrode surface by physical
adsorption, and then coated with capture antibody. Even though, the matrix of chitosanGOx only being attached on the electrode surface by non-specific physical interaction,
but the surface tension of chitosan is strong enough to hold the matrix with the electrode
surface. That is also explained the superiority of chitosan in molecule immobilization.
But in this scenario, the electron transfer will be hindered by the antibody coverage, since
the chitosan- GOx was constructed beneath the capture antibody layer.
Another method to immobilized GOx is to mix with BSA first and then use
glutaraldehyde as the cross-link to form a gel texture increasing the surface tension,
which will proving stable and insoluble binding.
As shown in Figure 5.4 (a), the current and time response curves of chitosan- GOx and
GOx-BSA. Chitosan- GOx has high sensitivity and larger range of detection linearity,
which can be cause by the amount of GOx, since the GOx-BSA only exists in the
blocking buffer.
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Figure 5.4 (a) Glucose current-time current response curves (b) standard
calibration curve.
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5.3.3 Feasibility study: HRP determination
5.3.3.1

Cyclic voltammetry study of TMB and HQ for HRP

As shown in Figure 5.5, HRP catalyze the reaction between TMB and H2O2 will consume
H2O2 and Hydrogen ions. The same theory of HQ based immunoassay. However, as
shown in the Figure 5.6 and Figure 5.7, there is not obvious current change in peak
current when adding glucose in the immunosensor. It might be caused by the following
possible reason: First, the pH range may not suitable for both GOx and HRP, either of
them lost bioactivity can cause no response. Secondly, the sandwich type of antibodyantigen-antibody complex will hinder the electron transferring, which will cause the
blank response.

Figure 5.5: Schematic of Horseradish peroxidase catalysis TMB.
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Figure 5.6 : Cyclic voltammograms of 0.2 Mm TMB in citrate-phosphatase buffer
(pH 5.0). (a) 10 mM glucose; (b) 5 mM glucose; (C) 0 mM glucose.

Figure 5.7: Cyclic voltammograms of 0.3 Mm HQ in PBS buffer (pH 7.0) + 0.1 M
KCl. (a) PBS-KCl; (b) PBS-KCl-HQ; (c) PBS-KCl-HQ- glucose (5mM).
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A preliminary calibration plot was established of HRP-based immunosensor in TMB
liquid substrate (pH 5.3) purchased form Sigma. The triangle and dot stands for adding
H2O2 instead of glucose and the square is the signal generated by adding glucose. The
triangle also without any GOx coating involved, and presents the best sensitivity among
all the three. Therefore, to combine with glucose sensor and immunosensor will need
further discussion or improvements.

Figure 5.4: HRP-labeled enzyme in HQ-PBS liquid substrate. (Triangle) H2O2 of
TMB reaction detection cTnI PDDA-MWCNT (Dot) ) H2O2 of TMB reaction
detection cTnI on chitosan-GOx. (Square) Glucose in immunoassay.
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5.3.4 Multimarker concept
Multianalyte is the new trend in diagnostic technology development due to the
comprehensive results, cost effective (comparing to several consumable in one package),
ease-to-use, and labor efficiency.
Simultaneously

immunoassay,

the

multianalyte

immunoassay

uses

arrays

of

immunosensing electrodes, each capable of performing an independent electrochemical
immunoassay for a specific analyte. Each electrode contains immobilized antibodies and
uses an AP-based enzyme-linked immunosorbent assay (ELISA) to measure analyte
concentration. Amperometric responses are produced at the electrodes due to the
electrochemical oxidization of redox mediator, and the size of the response enables the
quantification of analytes. (Wilson, 2005).
Successively assay, the multianalyte assay uses arrays of immunosensing electrodes and
enzyme sensor, the electroactive substrate produced by enzyme sensor can be utilized in
immunoassay. For example, the HRP-based immunosensor can the integrated with
glucose sensor or lactase sensor, which relying on detection H2O2 concentration to
establish linear proportional relationship between electrochemical signal and glucose
concentration. However, H2O2 also plays a significant role in immunoassay for HRPbased biosensor: neither TMB nor HQ detecting systems can be functional without H2O2.

5.4

Conclusion

Based on sandwich ELISA and glucose biosensor, we tried to integrate these enzyme
biosensors into one chip. But the results may not show as promising as expected; the
sensitivity was limited by the electron transferring by the inactive layer. In order to
improvement the experiments, we design to utilize high concentration of the glucose
oxidize along with the spatial arrangement of the immunosensor.
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Chapter 6
6

Summary and outlook

6.1

Summary

The object of this thesis is to design and develop an electrochemical immunosensor for
the specific and sensitive detection of cardiac troponin I with low cost, robustness, timeefficiency and easy-to-operate.
Because amperometric response was obtained through four critical procedures including
electrode modification, immunoreaction, signal amplification and amperometric
detection, then the immunosensor was investigated by procedures.
First, carbon nanotube (CNT), chitosan and gold nanoparticle (AuNP) were used to
modify electrode and to explore the variation in electrochemical behaviors. Experiment
conditions were optimized and interferences were investigated. The detection range
investigated using cyclic voltammetry (CV) was 0.01 ng/ml to 300 ng/ml on PDDAMWCNT sensor, 0.001 ng/ml to 500 ng/ml on chitosan-AuNP sensor, respectively.
Also, the recorded behavior was linear in the signal versus cTnI concentration, indicating
great potential for clinical application.
Second, enzyme labels for signal amplification, ALP and HRP, were studied respectively.
Hydrogen peroxide (H2O2) is not only the product of glucose oxidize (GOx) catalyzing
the oxidation of β-D-glucose by oxygen, but also the needful oxidizing agent in HRP
catalysis. Therefore, potentially, HRP-based immunosensor is suitable to integrate
immunosensor and enzyme sensor to realize multianalyte detection compacted on one
chip. The feasibility was verified by the influence of H2O2 concentration of HRP-based
biosensor and H2O2 quantification on immunosensor with blocking by GOx-BSA.
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6.2

Thesis contributions

The immunosensor developed here is an cost-effective, robust and simple-to-use
approach to detect cardiac troponin I concentration for cardiac condition diagnostics,
especially for point-of-care settings.
A comprehensive investigation has been carried out for experimental variables including
nanomaterials modification, experimental condition (temperature, incubation time, pH
value and etc.), labeled enzyme, signal generating substrates, and simplifying the
detection procedures.
In addition, a concept has been proposed for simultaneously and successively multiplex
platform immunosensor. The feasibility was investigated by cTnI immunosensor blocked
by GOx-BSA

6.3

Recommendation for future work

One of the most critical objects of this research is to design and develop a CD-platform
electrochemical immunosensor for the multiple cardiac biomarkers detection over a wide
concentration range along with low detection limits and high sensitivity.
The work showed cTnI immunosensor to be ready for further integrating: Firstly, it can
be adapted cTnI immunosensor with blood separation device for an automated whole
cardiac diagnostic chip. Secondly, it can be combined with other cardiac biomarkers,
such like myoglobin, C - reactive protein (CRP), CK-MB and etc., for diagnosing certain
type or stage of cardiac conditions. Thirdly, it can be processed together with glucose,
carbamide or lactose sensor for cardiac postoperative vital signs monitoring.
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